JP4709873B2 - ナノ粒子組成物 - Google Patents
ナノ粒子組成物 Download PDFInfo
- Publication number
- JP4709873B2 JP4709873B2 JP2008138475A JP2008138475A JP4709873B2 JP 4709873 B2 JP4709873 B2 JP 4709873B2 JP 2008138475 A JP2008138475 A JP 2008138475A JP 2008138475 A JP2008138475 A JP 2008138475A JP 4709873 B2 JP4709873 B2 JP 4709873B2
- Authority
- JP
- Japan
- Prior art keywords
- anticancer agent
- surface modifier
- particle size
- composition
- less
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B82—NANOTECHNOLOGY
- B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
- B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
- A61K47/6921—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere
- A61K47/6923—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being an inorganic particle, e.g. ceramic particles, silica particles, ferrite or synsorb
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
- A61K47/6921—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere
- A61K47/6927—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores
- A61K47/6929—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores the form being a nanoparticle, e.g. an immuno-nanoparticle
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/04—X-ray contrast preparations
- A61K49/0409—Physical forms of mixtures of two different X-ray contrast-enhancing agents, containing at least one X-ray contrast-enhancing agent which is not a halogenated organic compound
- A61K49/0414—Particles, beads, capsules or spheres
- A61K49/0423—Nanoparticles, nanobeads, nanospheres, nanocapsules, i.e. having a size or diameter smaller than 1 micrometer
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/04—X-ray contrast preparations
- A61K49/0409—Physical forms of mixtures of two different X-ray contrast-enhancing agents, containing at least one X-ray contrast-enhancing agent which is not a halogenated organic compound
- A61K49/0414—Particles, beads, capsules or spheres
- A61K49/0423—Nanoparticles, nanobeads, nanospheres, nanocapsules, i.e. having a size or diameter smaller than 1 micrometer
- A61K49/0428—Surface-modified nanoparticles, e.g. immuno-nanoparticles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/04—X-ray contrast preparations
- A61K49/0433—X-ray contrast preparations containing an organic halogenated X-ray contrast-enhancing agent
- A61K49/0447—Physical forms of mixtures of two different X-ray contrast-enhancing agents, containing at least one X-ray contrast-enhancing agent which is a halogenated organic compound
- A61K49/0476—Particles, beads, capsules, spheres
- A61K49/0485—Nanoparticles, nanobeads, nanospheres, nanocapsules, i.e. having a size or diameter smaller than 1 micrometer
- A61K49/049—Surface-modified nanoparticles, e.g. immune-nanoparticles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
- A61K9/145—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
- A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
Description
加えて、弱水溶性の薬剤、例えば、弱水溶性抗癌剤は静脈内(IV) ボーラス注射で容易に注射可能ではない。弱可溶性薬剤の注射可能な形状への創造は、侮り難い課題の代表である。弱可溶性薬剤、例えば、弱可溶性抗癌剤をIVボーラス注射可能な形状で提供できるようにすることが強く望まれている。
より詳細には、本発明に従って、実質的に、約1000nm未満の平均有効粒子径を維持するのに充分な量で表面上に表面修飾剤を吸着せしめた結晶状抗癌剤から成る粒子が提供される。
本発明の別の態様では、前記抗癌性組成物を哺乳動物に投与することを含んで成る哺乳動物の治療方法を提供する。
本発明の更に別の態様では、前記粒子の形で該薬剤を投与する段階を包含する抗癌剤の有効性を増大する方法及び/又は毒性を低減する方法を提供する。
抗癌性組成物が改良された有効性を示すことは、本発明の別の有利な特徴である。
本発明のまた別の有利な特徴は、組成物が、IVボーラス注射によって投与できる弱可溶性抗癌剤を特徴とすることである。
本発明の更に又別の有利な特徴は、組成物が、IVボーラス注射後に血液プール中の循環延長を示す弱可溶性抗癌剤を含有することである。
置換アジリジンを有するアルキル化剤、例えば、トレタミン、チオテパ、トリアジキノン及びマイトマイシン;
アルキルスルホネート型のアルキル化剤、例えば、ブスルファン、ピポスルファン及びピポスルファム;
アルキル化N−アルキル−N−ニトロソウレア誘導体、例えば、カルムスチン、ロムスチン、セムスチンもしくはストレプトゾトシン;並びに
ミトブロニトール、ダカルバジン及びプロカルバジン型のアルキル化剤が挙げられる。
ピリミジン類似体類、例えば、フルオロウラシル、フロクスウリジン、テガフール、シタラビン、イドクスウリジン及びフルシトシン;並びに
プリン誘導体類、例えば、メルカプトプリン、チオグアニン、アザチオプリン、チアミプリン、ビダラビン、ペントスタチン及びピューロマイシンが挙げられる。
エピポドフィロトキシン類、例えば、エトポシド及びテニポシド;
抗生物質類、例えば、アドリアマイシン、ダウノマイシン、ダクチノマイシン、ダウノルビシン、ドキソルビシン、ミスラマイシン、ブレオマイシン及びマイトマイシン;
酵素類、例えば、L−アスパラギナーゼ;
生体応答調節物質類、例えば、α−インターフェロン;
カンプトテシン;
タキソル;並びに
レチノイド類、例えば、レチノイン酸が挙げられる。
プロゲスチン類、例えば、カプロン酸ヒドロキシプロゲステロン、酢酸メドロキシプロゲステロン及び酢酸メゲストロール;
エストロゲン類、例えば、ジエチルスチルベストロール及びエチニルエストラジオール;
抗エストロゲン類、例えば、タモキシフェン;
アンドロゲン類、例えば、プロピオン酸テストステロン及びフルオキシメステロン;
抗アンドロゲン類、例えば、フルタミド;並びに
ゴナドトロピン放出性ホルモン類似体類、例えば、ロイプロリドが挙げられる。
白金配位錯体類、例えば、シスプラチン及びカルボプラチン;
アントラセンジオン類、例えば、ミトキサントロン;
置換尿素類、例えば、ヒドロキシウレア;並びに
副腎皮質抑制剤類、例えば、マイトテイン及びアミノグルテチミドが挙げられる。
本発明の実施に際して有用な抗癌剤は既知化合物であるか、及び/又は当該技術分野で既知である技術によって製造できる。
本発明の粒子は、それらの表面上に表面修飾剤を吸着せしめた前記抗癌剤を含む。有用な表面修飾剤は、抗癌剤の表面に物理的に付着するが抗癌剤に対して化学的に結合しないものを包含すると信じられている。
粉砕用容器:8oz. ( 250mL) ガラスジャー
粉砕用容器の許容容量: 250mL
媒体容量: 120mL
媒体タイプ: 1.0mmの予備洗浄済酸化ジルコニウムビーズ
(Zircoa, Inc.市販)
微粉砕時間: 120時間
スラリー容量:60mL
RPM:92
室温
実施例1〜4 ピポスルファンのナノ粒子
実施例1
ピポスルファン(Eastman Kodak より購入)を、0.33%ポリオキシエチレンソルビタンモノオレアート,Tween 80,(ICI Americas, Inc., Wilmington, DE)及び0.67%ソルビタンモノオレアート、Span 80 ,(ICI) の混合物中、1mm酸化ジルコニウムビーズを用いて約96時間微粉砕して直径およそ 240nmの粒子を生成した。懸濁液中の最終ピポスルファン濃度は 10mg/mlであった。粒子はラット血漿中凝集/凝結に対して安定であった。
実施例1は 10mg/ml懸濁液として直接注射できる。一回量 78mg/kgの注射後に急性毒性は全く認められなかった。
Tween 80対Span 80 の比が2:1であったことを除いて、実施例1に記載された微粉砕方法を繰り返した。得られた平均粒子径は 297nmであった。
Tween 80対Span 80 の比が1:1であったことを除いて、実施例1に記載された微粉砕方法を繰り返した。得られた平均粒子径は 380nmであった。
表面修飾剤のTween 60対Span 60 の比が1:1であったことを除いて、実施例1に記載された微粉砕方法を繰り返した。得られた平均粒子径は 301nmであった。
また表面修飾剤としてウシ血清アルブミンを用いて安定なピポスルファンナノ粒子を製造した。
実施例5
予備洗浄した酸化ジルコニウムビーズ(1mm)およそ60mLを 120mL広口丸底アンバーボトルにいれた。それにTetronic 908(BASF) 0.35gを添加し、続いてカンプトテシン(Sigma Chemicals ,純度95%)0.35gを添加した。前記混合物に注射用水(Abbott) 35mLを添加した。ボトルに封をしてローラーミルにかけた。 100 RPMで7日間ボトルを回転せしめることによって微粉砕を行った。
微粉砕の終了時に、アリコート( 100μL)についてMalvern Zetasizer を用いて粒子径のチェックをした。粒子を測定すると平均粒子径 240nmであった。
Tetronic 908をポリビニルアルコール(MW 30 〜70 K)に置き換えたことを除いて実施例5を繰り返した。最終粒子径は 256nmであった。
Tetronic 908をアラビアゴムに置き換えたことを除いて実施例5を繰り返した。最終粒子径は 298nmであった。
** 対照動物についての%T/Cは生存動物より求めた,N=2。
有効性増大が薬物動態特性の変化に関連するかどうか、乳房腺癌#16/Cのネズミの腫瘍モデルにおける血液クリアランス及び腫瘍分布を求めることで調査した。
腫瘍保持マウスに、実施例5及び6に記載のように製剤されたカンプトテシン 10mg/ml並びに 0.1N NaOH の添加により溶解せしめたカンプトテシン5mg/ml の対照を尾静脈に注射した。注射後多様な時間、すなわち、5分間、30分間、60分間、2時間、8時間、16時間、24時間及び48時間後に動物を安楽死させ、そして血液サンプルを採取しそして腫瘍を摘出した。薬剤サンプルの濃度をHPLCを用いて定量した。結果は、本発明の組成物が血液の循環プール及び腫瘍由来の薬剤のクリアランスに影響を及ぼすことを示した。
実施例8
エトポシド 1.7gを PVA 1.7gと合わせ、そして微粉砕時間を14日間にしたことを除いて実施例5を繰り返した。最終粒子径は 310nmであった。粒子は酸及び血漿中で安定であった。
PVAをPluronic F-108 (BASF) に置き換えたことを除いて実施例8を繰り返した。最終粒子径は 312nmであった。粒子は酸及び血漿中で安定であった。
エトポシド(2%)を滅菌水中で7日間微粉砕した。微粉砕したスラリーの1:1混合物を2%Pluronic F127 溶液で調整した。混合物を攪拌した後に粒子径を測定した。最終サイズは 277nmであった。スラリーは疑似胃液、PBS(pH 7.4)及びラット血漿中で安定であった。
ナノエトポシド製剤を膵管腺癌#03(PANC #03)における2つの別個の有効性調査で評価した。対照Cは、Physicians' Desk Reference,第46版, 741〜743 ページに記載される処方を用いて調整した2%非水性エトポシド溶液であった。上述のように、実験及び対照動物由来の腫瘍重量をモニターすることによって抗腫瘍活性を評価した。これらの調査は、本発明のエトポシド組成物が厳密な毒性反応で実証することなく高用量の薬剤を排出するための手段を提供することを具体的に示している。
実施例11
予備洗浄した酸化ジルコニウム媒体(1mm)およそ18mLを30mLアンバージャーに添加した。それにタキソル (Sigma Chemicals) 240mg及びTween 20 180mgを添加した。最後に、注射用水12mLをジャーに添加し、それを封じそしてローラーミルに11日間かけた。最終粒子径は 327nmであった。PBS(pH 7.4)及びラット血漿に暴露したときに、製剤は安定であった。
Tween 20を PVA (MW 30 〜70 k) に置き換えたことを除いて実施例11を繰り返した。最終粒子径は 365nmであった。
実施例17〜18 WIN 59075 のナノ粒子
予備洗浄した酸化ジルコニウム媒体(1mm)およそ60mLを4oz( 120ml)アンバージャーに移した。それに続いてWIN 59075 1.5g及び注射用水28.5mLを添加した。ジャーに封をし、ローラーミルに置き、そして95 RPMで48時間瀑落せしめた。PCS分析で粒子径を求めると 322nmであったが、しかしながら巨大粒子が認められた。微粉砕を更に5日間続けた。
実施例19〜22 SR 4889 のナノ粒子
SR 4889 18.75g及び水3.75mLと共に、予備洗浄した酸化ジルコニウム媒体(1mm) 7.5mLを15mLアンバージャーに移した。11日間微粉砕後、ナノ懸濁液を媒体から分離した。各懸濁液のアリコート 100μLに界面活性剤溶液(2%) 100μLを添加して最終濃度0.25%薬剤及び1%界面活性剤とした。混合物を攪拌しそして粒子径について分析した。懸濁液10μLをラット血漿90μLと混合せしめることにより流体安定性を顕微鏡で評価した。結果は以下のとおりであった。
予備洗浄した酸化ジルコニウム媒体30mLを60mLアンバージャーに移した。それにトランスレチノイン酸(Sigma)1g、チロキサポール 470mg及び水15mLを添加した。混合物をローラーミルで15日間微粉砕した。最終粒子径は 140nmであった。ナノ懸濁液は、ラット血漿及び疑似胃液のどちらかに暴露したときは安定であった。
Claims (20)
- 下記成分(a)及び(b):
(a)クロロメチン、クロラムブシル、メルファラン、ウラムスチン、燐酸エキストラムスチン、メクロレタミンオキシド、イホスファミド、トリホスファミド、トレタミン、トリアジクオン、ミトマイシン、ブスルファン、カルムスチン、ロムスチン、セムスチン、ストレプトゾトシン、ミトブロニトール、ダカルバジン、プロカルバジン、フルオロウラシル、フロクスウリジン、テガフール、シタラビン、イドクスウリジン、フルシトシン、メルカプトプリン、チオグアニン、アザチオプリン、チアミプリン、ビダラビン、ペントスタチン、ピューロマイシン、ビンブラスチン、ビンクリスチン、テニポシド、アドリアマイシン、ダウノマイシン、ドクチノマイシン、ミスラマイシン、ブレオマイシン、ミトマイシン、L−アスパラギナーゼ、α−インターフェロン、レチノイン酸、プレドニソン、カプロン酸ヒドロキシプロゲステロン、酢酸メドロキシプロゲステロン、酢酸メゲストロール、ジエチルスチルベストロール、エチニルエストラジオール、タモキシフェン、プロピオン酸テストステロン、フルオキシメステロン、フルタミド、ロイプロリド、シスプラチン、カルボプラチン、ミトキサントロン、ヒドロキシウレア、マイトテイン、アミノグルエチミド、アザチオプリン、スルファサァジン、メトキサレン及びサリドマイドからなる群より選ばれた、水への溶解度が室温で10mg/mL未満である結晶性抗癌剤、並びに
(b)平均粒径を400nm未満に維持せしめるに十分な量で前記抗癌剤の表面に吸着した少なくとも一種の無架橋表面修飾剤
を含んで成る安定なナノ粒子組成物であって、
該粒子はその粒子サイズを該表面修飾剤の存在下で機械的手段により低減して得られ、
該抗癌剤の存在量が、該抗癌剤と該表面修飾剤との合計質量を基準として99.9%〜10%の範囲内にあり、
該表面修飾剤の存在量が、該抗癌剤と該表面修飾剤との合計質量を基準として0.1%〜90%の範囲内にあり、かつ、該粒子の90質量%以上が400nm未満の平均粒子サイズを有することを維持するのに十分な量であり、そして
該粒子を含む分散体が、その調製後2日以上裸眼で観察できる凝集沈殿または粒子凝集を示さない
ことを特徴とするナノ粒子組成物。 - 前記ナノ粒子の平均粒径が300nm未満である、請求項1に記載の組成物。
- 前記組成物が注射可能である、請求項1又は2に記載の組成物。
- 前記少なくとも一種の表面修飾剤が、ゼラチン、カゼイン、レシチン、アラビアゴム、コレステロール、トラガカント、ステアリン酸、塩化ベンザルコニウム、ステアリン酸カルシウム、グリセリルモノステアレート、セトステアリルアルコール、セトマクロゴル乳化ワックス、ソルビタンエステル、ポリオキシエチレンアルキルエーテル、ポリオキシエチレンヒマシ油誘導体、ポリオキシエチレンソルビタン脂肪酸エステル、ポリエチレングリコール、ポリオキシエチレンステアレート、コロイド二酸化珪素、ホスフェート、ドデシル硫酸ナトリウム、カルボキシメチルセルロースカルシウム、カルボキシメチルセルロースナトリウム、メチルセルロース、ヒドロキシエチルセルロース、ヒドロキシプロピルセルロース、ヒドロキシプロピルメチルセルロースフタレート、非晶質セルロース、珪酸アルミニウムマグネシウム、トリエタノールアミン、ポリビニルアルコール(PVA)、ポリビニルピロリドン(PVP)、チロキサポール、ポロキサマー、ポロキサミン、デキストラン、スルホコハク酸ナトリウムのジオクチルエステル、ラウリル硫酸ナトリウム、アルキルアリールポリエーテルスルホネート、脂肪酸のソルビタンエステル、ステアリン酸スクロースとジステアリン酸スクロースの混合物、ヘキシルデシルトリメチルアンモニウムクロリド、ウシ血清アルブミン、エチレンジアミンにエチレンオキシドとプロピレンオキシドを逐次付加して得られた4官能性ブロックコポリマー、及びエチレンオキシドとプロピレンオキシドのブロックコポリマーからなる群より選ばれた、請求項1〜3のいずれか一項に記載の組成物。
- 前記抗癌剤がレチノイン酸である、請求項1〜4のいずれか一項に記載の組成物。
- 前記抗癌剤がレチノイン酸であり、且つ前記表面修飾剤がチロキサポールである、請求項1〜5のいずれか一項に記載の組成物。
- さらに第二の表面修飾剤を含む、請求項1〜6のいずれか一項に記載の組成物。
- さらに医薬用担体を含む、請求項1〜7のいずれか一項に記載の組成物。
- 固形剤もしくは液剤状態での経口投与用、非経口的注射用、直腸投与用、鼻腔内投与用、筋肉内投与用又は皮下投与用に処方された、請求項1〜8のいずれか一項に記載の組成物。
- (a)水への溶解度が室温で10mg/mL未満である弱可溶性の結晶性抗癌剤を液体分散媒に分散させ、
(b)前記抗癌剤を硬質粉砕媒体の存在下で湿式摩砕し、その後
(c)前記抗癌剤に少なくとも一種の無架橋表面修飾剤を接触させて当該表面修飾剤を前記抗癌剤の表面に吸着せしめることにより、平均粒径400nm未満の抗癌剤粒子を形成させることを特徴とする、請求項1〜9のいずれか一項に記載の安定な組成物の製造方法。 - (a)水への溶解度が室温で10mg/mL未満である弱可溶性の結晶性抗癌剤を液体分散媒に分散させ、そして
(b)前記抗癌剤を硬質粉砕媒体と少なくとも一種の無架橋表面修飾剤の存在下で湿式摩砕して当該表面修飾剤を前記抗癌剤の表面に吸着せしめることにより、平均粒径400nm未満の抗癌剤粒子を形成させることを特徴とする、請求項1〜8のいずれか一項に記載の安定な組成物の製造方法。 - 前記硬質粉砕媒体が、酸化ジルコニウム、珪酸ジルコニウム、ガラス、ステンレススチール、チタニア及びアルミナからなる群より選ばれる、請求項10又は11に記載の方法。
- 前記硬質粉砕媒体が球状である、請求項10〜12のいずれか一項に記載の方法。
- 前記硬質粉砕媒体の平均粒径が3mm未満である、請求項10〜13のいずれか一項に記載の方法。
- 前記硬質粉砕媒体の平均粒径が1mm未満である、請求項10〜14のいずれか一項に記載の方法。
- 前記硬質粉砕媒体の密度が2.5g/cm3より高い、請求項10〜15のいずれか一項に記載の方法。
- 前記湿式粉砕が分散ミル又は媒体ミルにおいて行われる、請求項10〜16のいずれか一項に記載の方法。
- 前記ミルがボールミル、摩砕ミル、振動ミル、遊星形ミル、サンドミル又はビーズミルである、請求項17に記載の方法。
- 前記湿式粉砕が周囲温度において行われる、請求項10〜18のいずれか一項に記載の方法。
- 前記湿式粉砕が冷却条件下で行われる、請求項10〜18のいずれか一項に記載の方法。
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US07/908,125 US5399363A (en) | 1991-01-25 | 1992-07-01 | Surface modified anticancer nanoparticles |
US908125 | 1992-07-01 |
Related Parent Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP5158808A Division JPH07165562A (ja) | 1992-07-01 | 1993-06-29 | 表面を修飾された抗癌性ナノ粒子 |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2010186927A Division JP2010265324A (ja) | 1992-07-01 | 2010-08-24 | ナノ粒子組成物 |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2008231119A JP2008231119A (ja) | 2008-10-02 |
JP4709873B2 true JP4709873B2 (ja) | 2011-06-29 |
Family
ID=25425237
Family Applications (3)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP5158808A Pending JPH07165562A (ja) | 1992-07-01 | 1993-06-29 | 表面を修飾された抗癌性ナノ粒子 |
JP2008138475A Expired - Lifetime JP4709873B2 (ja) | 1992-07-01 | 2008-05-27 | ナノ粒子組成物 |
JP2010186927A Pending JP2010265324A (ja) | 1992-07-01 | 2010-08-24 | ナノ粒子組成物 |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP5158808A Pending JPH07165562A (ja) | 1992-07-01 | 1993-06-29 | 表面を修飾された抗癌性ナノ粒子 |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2010186927A Pending JP2010265324A (ja) | 1992-07-01 | 2010-08-24 | ナノ粒子組成物 |
Country Status (24)
Country | Link |
---|---|
US (2) | US5399363A (ja) |
EP (1) | EP0577215B1 (ja) |
JP (3) | JPH07165562A (ja) |
KR (1) | KR940001881A (ja) |
CN (1) | CN1063630C (ja) |
AT (1) | ATE190835T1 (ja) |
AU (1) | AU675432B2 (ja) |
CA (1) | CA2098242C (ja) |
CZ (1) | CZ131693A3 (ja) |
DE (1) | DE69328136T2 (ja) |
DK (1) | DK0577215T3 (ja) |
ES (1) | ES2143488T3 (ja) |
FI (1) | FI933040A (ja) |
HU (1) | HUT64832A (ja) |
IL (1) | IL106198A0 (ja) |
MX (1) | MX9303950A (ja) |
MY (1) | MY109946A (ja) |
NO (1) | NO308193B1 (ja) |
NZ (1) | NZ248042A (ja) |
RU (1) | RU2130781C1 (ja) |
SG (1) | SG55089A1 (ja) |
SK (1) | SK281608B6 (ja) |
TW (1) | TW281631B (ja) |
UA (1) | UA27746C2 (ja) |
Families Citing this family (564)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6515009B1 (en) | 1991-09-27 | 2003-02-04 | Neorx Corporation | Therapeutic inhibitor of vascular smooth muscle cells |
US5811447A (en) | 1993-01-28 | 1998-09-22 | Neorx Corporation | Therapeutic inhibitor of vascular smooth muscle cells |
US6395494B1 (en) | 1993-05-13 | 2002-05-28 | Neorx Corporation | Method to determine TGF-β |
US6306421B1 (en) | 1992-09-25 | 2001-10-23 | Neorx Corporation | Therapeutic inhibitor of vascular smooth muscle cells |
US6251920B1 (en) | 1993-05-13 | 2001-06-26 | Neorx Corporation | Prevention and treatment of cardiovascular pathologies |
US6277410B1 (en) * | 1992-10-08 | 2001-08-21 | Supratek Pharma Inc. | Copolymer compositions for oral delivery |
FR2697752B1 (fr) * | 1992-11-10 | 1995-04-14 | Rhone Poulenc Rorer Sa | Compositions antitumorales contenant des dérivés du taxane. |
US5298262A (en) * | 1992-12-04 | 1994-03-29 | Sterling Winthrop Inc. | Use of ionic cloud point modifiers to prevent particle aggregation during sterilization |
US5346702A (en) * | 1992-12-04 | 1994-09-13 | Sterling Winthrop Inc. | Use of non-ionic cloud point modifiers to minimize nanoparticle aggregation during sterilization |
FR2698871B1 (fr) | 1992-12-09 | 1995-02-24 | Rhone Poulenc Rorer Sa | Nouveau taxoïdes, leur préparation et les compositions pharmaceutiques qui les contiennent. |
US6491938B2 (en) | 1993-05-13 | 2002-12-10 | Neorx Corporation | Therapeutic inhibitor of vascular smooth muscle cells |
US5981568A (en) | 1993-01-28 | 1999-11-09 | Neorx Corporation | Therapeutic inhibitor of vascular smooth muscle cells |
US6663881B2 (en) | 1993-01-28 | 2003-12-16 | Neorx Corporation | Therapeutic inhibitor of vascular smooth muscle cells |
US5525559A (en) * | 1993-02-13 | 1996-06-11 | Tioxide Specialties Limited | Preparation of mixed powders |
US6537579B1 (en) | 1993-02-22 | 2003-03-25 | American Bioscience, Inc. | Compositions and methods for administration of pharmacologically active compounds |
US6753006B1 (en) * | 1993-02-22 | 2004-06-22 | American Bioscience, Inc. | Paclitaxel-containing formulations |
US6096331A (en) | 1993-02-22 | 2000-08-01 | Vivorx Pharmaceuticals, Inc. | Methods and compositions useful for administration of chemotherapeutic agents |
US6749868B1 (en) | 1993-02-22 | 2004-06-15 | American Bioscience, Inc. | Protein stabilized pharmacologically active agents, methods for the preparation thereof and methods for the use thereof |
US20070117862A1 (en) * | 1993-02-22 | 2007-05-24 | Desai Neil P | Novel formulations of pharmacological agents, methods for the preparation thereof and methods for the use thereof |
US20030133955A1 (en) * | 1993-02-22 | 2003-07-17 | American Bioscience, Inc. | Methods and compositions useful for administration of chemotherapeutic agents |
US20030068362A1 (en) * | 1993-02-22 | 2003-04-10 | American Bioscience, Inc. | Methods and formulations for the delivery of pharmacologically active agents |
US5439686A (en) * | 1993-02-22 | 1995-08-08 | Vivorx Pharmaceuticals, Inc. | Methods for in vivo delivery of substantially water insoluble pharmacologically active agents and compositions useful therefor |
US5629327A (en) * | 1993-03-01 | 1997-05-13 | Childrens Hospital Medical Center Corp. | Methods and compositions for inhibition of angiogenesis |
US6228879B1 (en) | 1997-10-16 | 2001-05-08 | The Children's Medical Center | Methods and compositions for inhibition of angiogenesis |
US8143283B1 (en) * | 1993-03-01 | 2012-03-27 | The Children's Medical Center Corporation | Methods for treating blood-born tumors with thalidomide |
US6114355A (en) * | 1993-03-01 | 2000-09-05 | D'amato; Robert | Methods and compositions for inhibition of angiogenesis |
US5830436A (en) * | 1993-03-30 | 1998-11-03 | Duke University | Method of mucociliary clearance in cystic fibrosis patients using alkylaryl polyether alcohol polymers |
US5840277A (en) * | 1993-03-30 | 1998-11-24 | Charlotte Hospital Authority | Treatment of chronic pulmonary inflammation |
US5849263A (en) * | 1993-03-30 | 1998-12-15 | Charlotte-Mecklenburg Hospital Authority | Pharmaceutical compositions containing alkylaryl polyether alcohol polymer |
CH686761A5 (de) | 1993-05-27 | 1996-06-28 | Sandoz Ag | Galenische Formulierungen. |
US6441026B1 (en) | 1993-11-08 | 2002-08-27 | Aventis Pharma S.A. | Antitumor compositions containing taxane derivatives |
US5534270A (en) * | 1995-02-09 | 1996-07-09 | Nanosystems Llc | Method of preparing stable drug nanoparticles |
US5573783A (en) * | 1995-02-13 | 1996-11-12 | Nano Systems L.L.C. | Redispersible nanoparticulate film matrices with protective overcoats |
US5510118A (en) * | 1995-02-14 | 1996-04-23 | Nanosystems Llc | Process for preparing therapeutic compositions containing nanoparticles |
EP0810853B1 (en) * | 1995-02-24 | 2004-08-25 | Elan Pharma International Limited | Aerosols containing nanoparticle dispersions |
DE19512484A1 (de) * | 1995-04-04 | 1996-10-17 | Bayer Ag | Kohlenhydratmodifizierte Cytostatika |
US5731325A (en) * | 1995-06-06 | 1998-03-24 | Andrulis Pharmaceuticals Corp. | Treatment of melanomas with thalidomide alone or in combination with other anti-melanoma agents |
US7833543B2 (en) * | 1995-06-07 | 2010-11-16 | Durect Corporation | High viscosity liquid controlled delivery system and medical or surgical device |
US6413536B1 (en) | 1995-06-07 | 2002-07-02 | Southern Biosystems, Inc. | High viscosity liquid controlled delivery system and medical or surgical device |
WO1997004756A2 (en) * | 1995-07-26 | 1997-02-13 | Nanosystems L.L.C. | Methacrylate backbone surfactants in nanoparticulate formulations |
US6391338B1 (en) | 1995-09-07 | 2002-05-21 | Biovail Technologies Ltd. | System for rendering substantially non-dissoluble bio-affecting agents bio-available |
US5834025A (en) | 1995-09-29 | 1998-11-10 | Nanosystems L.L.C. | Reduction of intravenously administered nanoparticulate-formulation-induced adverse physiological reactions |
US6346510B1 (en) * | 1995-10-23 | 2002-02-12 | The Children's Medical Center Corporation | Therapeutic antiangiogenic endostatin compositions |
US5955509A (en) * | 1996-05-01 | 1999-09-21 | Board Of Regents, The University Of Texas System | pH dependent polymer micelles |
CN1219872A (zh) * | 1996-05-24 | 1999-06-16 | 血管技术药物公司 | 治疗或预防身体通道疾病的组合物和方法 |
US20030195848A1 (en) * | 1996-06-05 | 2003-10-16 | David Felger | Method of billing a purchase made over a computer network |
AU3585397A (en) | 1996-06-27 | 1998-01-14 | G.D. Searle & Co. | Particles comprising amphiphilic copolymers, having a cross-linked shell domain and an interior core domain, useful for pharmaceutical and other applications |
US7255877B2 (en) * | 1996-08-22 | 2007-08-14 | Jagotec Ag | Fenofibrate microparticles |
US6465016B2 (en) | 1996-08-22 | 2002-10-15 | Research Triangle Pharmaceuticals | Cyclosporiine particles |
US8137684B2 (en) * | 1996-10-01 | 2012-03-20 | Abraxis Bioscience, Llc | Formulations of pharmacological agents, methods for the preparation thereof and methods for the use thereof |
PT1586322E (pt) * | 1996-11-05 | 2008-10-27 | Childrens Medical Center | Composições que compreendem talidomida e dexametasona para o tratamento de cancro |
US6515016B2 (en) | 1996-12-02 | 2003-02-04 | Angiotech Pharmaceuticals, Inc. | Composition and methods of paclitaxel for treating psoriasis |
FR2759293B1 (fr) * | 1997-02-11 | 1999-04-30 | Ethypharm Lab Prod Ethiques | Microgranules contenant du cisplatine, procede de fabrication, preparation pharmaceutique et utilisation en polychimiotherapie ou en association avec une radiotherapie |
WO1998035666A1 (en) * | 1997-02-13 | 1998-08-20 | Nanosystems Llc | Formulations of nanoparticle naproxen tablets |
US6045829A (en) | 1997-02-13 | 2000-04-04 | Elan Pharma International Limited | Nanocrystalline formulations of human immunodeficiency virus (HIV) protease inhibitors using cellulosic surface stabilizers |
DK1014990T3 (da) * | 1997-03-07 | 2006-12-11 | Sanofi Aventis Us Llc | Antitumorkombination af 3 amino-1,2,4 benzotriazin-1,4 dioxid/paclitaxel/platin |
US20050004049A1 (en) * | 1997-03-11 | 2005-01-06 | Elan Pharma International Limited | Novel griseofulvin compositions |
AU6853498A (en) * | 1997-04-22 | 1998-11-13 | Nippon Kayaku Kabushiki Kaisha | Flutamide preparations and method for manufacturing the same |
US20020039594A1 (en) * | 1997-05-13 | 2002-04-04 | Evan C. Unger | Solid porous matrices and methods of making and using the same |
US6051558A (en) * | 1997-05-28 | 2000-04-18 | Southern Biosystems, Inc. | Compositions suitable for controlled release of the hormone GnRH and its analogs |
US20060025328A1 (en) * | 1997-05-28 | 2006-02-02 | Burns Patrick J | Compositions suitable for controlled release of the hormone GnRH and its analogs |
EP1023050B1 (en) * | 1997-06-27 | 2013-09-25 | Abraxis BioScience, LLC | Novel formulations of pharmacological agents, methods for the preparation thereof and methods for the use thereof |
US20030199425A1 (en) * | 1997-06-27 | 2003-10-23 | Desai Neil P. | Compositions and methods for treatment of hyperplasia |
US8853260B2 (en) * | 1997-06-27 | 2014-10-07 | Abraxis Bioscience, Llc | Formulations of pharmacological agents, methods for the preparation thereof and methods for the use thereof |
UA72189C2 (uk) | 1997-11-17 | 2005-02-15 | Янссен Фармацевтика Н.В. | Фармацевтична композиція, що містить водну суспензію субмікронних ефірів 9-гідроксирисперидон жирних кислот |
US20020147143A1 (en) | 1998-03-18 | 2002-10-10 | Corixa Corporation | Compositions and methods for the therapy and diagnosis of lung cancer |
US6673828B1 (en) * | 1998-05-11 | 2004-01-06 | Children's Medical Center Corporation | Analogs of 2-Phthalimidinoglutaric acid |
CN1245955C (zh) | 1998-05-29 | 2006-03-22 | 斯凯伊药品加拿大公司 | 热保护微粒组合物及其最终蒸汽灭菌的方法 |
US6153225A (en) * | 1998-08-13 | 2000-11-28 | Elan Pharma International Limited | Injectable formulations of nanoparticulate naproxen |
AU759641B2 (en) * | 1998-08-19 | 2003-04-17 | Skyepharma Canada Inc. | Injectable aqueous dispersions of propofol |
US6350786B1 (en) | 1998-09-22 | 2002-02-26 | Hoffmann-La Roche Inc. | Stable complexes of poorly soluble compounds in ionic polymers |
US20030235557A1 (en) | 1998-09-30 | 2003-12-25 | Corixa Corporation | Compositions and methods for WT1 specific immunotherapy |
US20040013613A1 (en) * | 2001-05-18 | 2004-01-22 | Jain Rajeev A | Rapidly disintegrating solid oral dosage form |
US20080213378A1 (en) * | 1998-10-01 | 2008-09-04 | Elan Pharma International, Ltd. | Nanoparticulate statin formulations and novel statin combinations |
US8293277B2 (en) * | 1998-10-01 | 2012-10-23 | Alkermes Pharma Ireland Limited | Controlled-release nanoparticulate compositions |
EP2266542A3 (en) * | 1998-10-01 | 2013-07-31 | Elan Pharma International Limited | Controlled release nanoparticulate compositions |
US8236352B2 (en) * | 1998-10-01 | 2012-08-07 | Alkermes Pharma Ireland Limited | Glipizide compositions |
US20070160675A1 (en) * | 1998-11-02 | 2007-07-12 | Elan Corporation, Plc | Nanoparticulate and controlled release compositions comprising a cephalosporin |
US20090297602A1 (en) * | 1998-11-02 | 2009-12-03 | Devane John G | Modified Release Loxoprofen Compositions |
NZ511442A (en) * | 1998-11-02 | 2003-02-28 | Elan Corp Plc | Multiparticulate modified release composition for multiple dosing of ADD patients with methylphenidate HCl |
US6969529B2 (en) | 2000-09-21 | 2005-11-29 | Elan Pharma International Ltd. | Nanoparticulate compositions comprising copolymers of vinyl pyrrolidone and vinyl acetate as surface stabilizers |
US6375986B1 (en) | 2000-09-21 | 2002-04-23 | Elan Pharma International Ltd. | Solid dose nanoparticulate compositions comprising a synergistic combination of a polymeric surface stabilizer and dioctyl sodium sulfosuccinate |
US7521068B2 (en) * | 1998-11-12 | 2009-04-21 | Elan Pharma International Ltd. | Dry powder aerosols of nanoparticulate drugs |
US6428814B1 (en) | 1999-10-08 | 2002-08-06 | Elan Pharma International Ltd. | Bioadhesive nanoparticulate compositions having cationic surface stabilizers |
US20040141925A1 (en) * | 1998-11-12 | 2004-07-22 | Elan Pharma International Ltd. | Novel triamcinolone compositions |
US6984404B1 (en) | 1998-11-18 | 2006-01-10 | University Of Florida Research Foundation, Inc. | Methods for preparing coated drug particles and pharmaceutical formulations thereof |
KR20010073232A (ko) | 1998-11-20 | 2001-07-31 | 추후제출 | 분산성 인지질로 안정화된 마이크로입자 |
US20040009535A1 (en) | 1998-11-27 | 2004-01-15 | Celltech R&D, Inc. | Compositions and methods for increasing bone mineralization |
WO2000032773A1 (en) | 1998-11-27 | 2000-06-08 | Darwin Discovery Ltd. | Compositions and methods for increasing bone mineralization |
DE19856432A1 (de) | 1998-12-08 | 2000-06-15 | Basf Ag | Nanopartikuläre Kern-Schale Systeme sowie deren Verwendung in pharmazeutischen und kosmetischen Zubereitungen |
US6040330A (en) * | 1999-01-08 | 2000-03-21 | Bionumerik Pharmaceuticals, Inc. | Pharmaceutical formulations of taxanes |
US6267989B1 (en) | 1999-03-08 | 2001-07-31 | Klan Pharma International Ltd. | Methods for preventing crystal growth and particle aggregation in nanoparticulate compositions |
EP1754488A1 (en) | 1999-05-24 | 2007-02-21 | Introgen Therapeutics, Inc. | Methods and compositions for non-viral gene therapy for treatment of hyperproliferative diseases |
US6444223B1 (en) | 1999-05-28 | 2002-09-03 | Alkermes Controlled Therapeutics, Inc. | Method of producing submicron particles of a labile agent and use thereof |
US6406745B1 (en) * | 1999-06-07 | 2002-06-18 | Nanosphere, Inc. | Methods for coating particles and particles produced thereby |
US20090104273A1 (en) * | 1999-06-22 | 2009-04-23 | Elan Pharma International Ltd. | Novel nifedipine compositions |
US20040115134A1 (en) * | 1999-06-22 | 2004-06-17 | Elan Pharma International Ltd. | Novel nifedipine compositions |
US6656504B1 (en) * | 1999-09-09 | 2003-12-02 | Elan Pharma International Ltd. | Nanoparticulate compositions comprising amorphous cyclosporine and methods of making and using such compositions |
ES2241663T3 (es) * | 1999-09-21 | 2005-11-01 | Skyepharma Canada Inc. | Composiciones particuladas modificadas superficialmente de substancias biologicamente activas. |
EP2289549A3 (en) | 1999-10-01 | 2011-06-15 | Immunogen, Inc. | Immunoconjugates for treating cancer |
US20040009229A1 (en) * | 2000-01-05 | 2004-01-15 | Unger Evan Charles | Stabilized nanoparticle formulations of camptotheca derivatives |
EP1166225A1 (en) | 2000-01-31 | 2002-01-02 | Collaborative Technologies, Inc. | Method and system for producing customized cosmetic and pharmaceutical formulations on demand |
GB0002952D0 (en) * | 2000-02-09 | 2000-03-29 | Pharma Mar Sa | Process for producing kahalalide F compounds |
ATE487733T1 (de) | 2000-02-23 | 2010-11-15 | Glaxosmithkline Biolog Sa | Neue verbindungen |
US20040002068A1 (en) | 2000-03-01 | 2004-01-01 | Corixa Corporation | Compositions and methods for the detection, diagnosis and therapy of hematological malignancies |
US20040156872A1 (en) * | 2000-05-18 | 2004-08-12 | Elan Pharma International Ltd. | Novel nimesulide compositions |
US6316029B1 (en) | 2000-05-18 | 2001-11-13 | Flak Pharma International, Ltd. | Rapidly disintegrating solid oral dosage form |
US10293056B1 (en) | 2000-05-24 | 2019-05-21 | Board Of Regents, The University Of Texas System | Methods and compositions for non-viral gene therapy for treatment of hyperproliferative diseases |
ES2374620T3 (es) | 2000-06-20 | 2012-02-20 | Corixa Corporation | Antígeno mtb32a de mycobacterium tuberculosis con el sitio activo inactivado y proteínas de fusión de los mismos. |
EP1961819A3 (en) | 2000-06-28 | 2008-11-12 | Corixa Corporation | Composition and methods for the therapy and diagnosis of lung cancer |
US7276249B2 (en) * | 2002-05-24 | 2007-10-02 | Elan Pharma International, Ltd. | Nanoparticulate fibrate formulations |
US20030224058A1 (en) * | 2002-05-24 | 2003-12-04 | Elan Pharma International, Ltd. | Nanoparticulate fibrate formulations |
US7198795B2 (en) * | 2000-09-21 | 2007-04-03 | Elan Pharma International Ltd. | In vitro methods for evaluating the in vivo effectiveness of dosage forms of microparticulate of nanoparticulate active agent compositions |
US20080241070A1 (en) * | 2000-09-21 | 2008-10-02 | Elan Pharma International Ltd. | Fenofibrate dosage forms |
US7998507B2 (en) * | 2000-09-21 | 2011-08-16 | Elan Pharma International Ltd. | Nanoparticulate compositions of mitogen-activated protein (MAP) kinase inhibitors |
CN1469735A (zh) * | 2000-10-16 | 2004-01-21 | ����˹��ҩ�﹫˾ | 米托蒽醌的脂质体制剂 |
WO2002064083A2 (en) * | 2000-11-30 | 2002-08-22 | The Children's Medical Center Corporation | Synthesis of 3-amino-thalidomide and its enantiomers |
EP1404359A2 (en) * | 2000-12-07 | 2004-04-07 | Board Of Regents, The University Of Texas System | Methods of treatment involving human mda-7 |
US20040256749A1 (en) * | 2000-12-22 | 2004-12-23 | Mahesh Chaubal | Process for production of essentially solvent-free small particles |
US7193084B2 (en) * | 2000-12-22 | 2007-03-20 | Baxter International Inc. | Polymorphic form of itraconazole |
US7037528B2 (en) * | 2000-12-22 | 2006-05-02 | Baxter International Inc. | Microprecipitation method for preparing submicron suspensions |
US20040022862A1 (en) * | 2000-12-22 | 2004-02-05 | Kipp James E. | Method for preparing small particles |
US8067032B2 (en) * | 2000-12-22 | 2011-11-29 | Baxter International Inc. | Method for preparing submicron particles of antineoplastic agents |
US20050048126A1 (en) * | 2000-12-22 | 2005-03-03 | Barrett Rabinow | Formulation to render an antimicrobial drug potent against organisms normally considered to be resistant to the drug |
US6977085B2 (en) * | 2000-12-22 | 2005-12-20 | Baxter International Inc. | Method for preparing submicron suspensions with polymorph control |
US20030096013A1 (en) * | 2000-12-22 | 2003-05-22 | Jane Werling | Preparation of submicron sized particles with polymorph control |
US6951656B2 (en) * | 2000-12-22 | 2005-10-04 | Baxter International Inc. | Microprecipitation method for preparing submicron suspensions |
US6884436B2 (en) * | 2000-12-22 | 2005-04-26 | Baxter International Inc. | Method for preparing submicron particle suspensions |
US6623761B2 (en) | 2000-12-22 | 2003-09-23 | Hassan Emadeldin M. | Method of making nanoparticles of substantially water insoluble materials |
US20030072807A1 (en) * | 2000-12-22 | 2003-04-17 | Wong Joseph Chung-Tak | Solid particulate antifungal compositions for pharmaceutical use |
US9700866B2 (en) * | 2000-12-22 | 2017-07-11 | Baxter International Inc. | Surfactant systems for delivery of organic compounds |
DK1413331T3 (da) * | 2001-01-26 | 2007-12-10 | Schering Corp | Kombinationer af peroxisomproliferatoraktiveret receptor (PPAR)-aktivatoren fenofibrat og sterolabsorptionsinhibitoren ezetimib til vaskulære indikationer |
US20060287254A1 (en) * | 2001-01-26 | 2006-12-21 | Schering Corporation | Use of substituted azetidinone compounds for the treatment of sitosterolemia |
US6497896B2 (en) | 2001-02-12 | 2002-12-24 | Supergen, Inc. | Method for administering camptothecins via injection of a pharmaceutical composition comprising microdroplets containing a camptothecin |
US20020150615A1 (en) * | 2001-02-12 | 2002-10-17 | Howard Sands | Injectable pharmaceutical composition comprising microdroplets of a camptothecin |
US6509027B2 (en) | 2001-02-12 | 2003-01-21 | Supergen, Inc. | Injectable pharmaceutical composition comprising coated particles of camptothecin |
EP1372394A1 (en) | 2001-04-03 | 2004-01-02 | Schering Corporation | Antifungal composition with enhanced bioavailability |
CA2446788A1 (en) | 2001-05-09 | 2002-11-14 | Corixa Corporation | Compositions and methods for the therapy and diagnosis of prostate cancer |
US6976647B2 (en) * | 2001-06-05 | 2005-12-20 | Elan Pharma International, Limited | System and method for milling materials |
WO2003000228A2 (en) * | 2001-06-22 | 2003-01-03 | Elan Pharma International Ltd. | Method for high through put screening using a small scale mill or microfluidics |
US20030054042A1 (en) * | 2001-09-14 | 2003-03-20 | Elaine Liversidge | Stabilization of chemical compounds using nanoparticulate formulations |
PT1429731E (pt) * | 2001-09-19 | 2007-04-30 | Elan Pharma Int Ltd | Formulações de insulina nanoparticulada |
US7053080B2 (en) * | 2001-09-21 | 2006-05-30 | Schering Corporation | Methods and therapeutic combinations for the treatment of obesity using sterol absorption inhibitors |
DK1429756T3 (da) * | 2001-09-21 | 2007-03-19 | Schering Corp | Behandling af xanthoma med azetidinonderivater som sterolabsorptionsinhibitorer |
US20060003012A9 (en) * | 2001-09-26 | 2006-01-05 | Sean Brynjelsen | Preparation of submicron solid particle suspensions by sonication of multiphase systems |
EP1429749A2 (en) * | 2001-09-26 | 2004-06-23 | Baxter International Inc. | Preparation of submicron sized nanoparticles via dispersion and solvent or liquid phase removal |
DE60222160T2 (de) * | 2001-10-12 | 2008-06-12 | Elan Pharma International Ltd., Athlone | Zusammensetzungen mit einer kombination aus eigenschaften sofortiger freisetzung und kontrollierter freisetzung |
US20030087837A1 (en) * | 2001-10-15 | 2003-05-08 | Jonas Jeffrey M. | Compositions and methods for delivery of poorly water soluble drugs and methods of treatment |
US7112340B2 (en) * | 2001-10-19 | 2006-09-26 | Baxter International Inc. | Compositions of and method for preparing stable particles in a frozen aqueous matrix |
WO2003039601A1 (en) * | 2001-11-07 | 2003-05-15 | Imcor Pharmaceutical Company | Methods for vascular imaging using nanoparticulate contrast agents |
BR0117191A (pt) * | 2001-12-06 | 2005-05-10 | Ranbaxy Lab Ltd | Composições nanoparticuladas de isotretinoina |
UA76810C2 (uk) * | 2001-12-10 | 2006-09-15 | Мерк Енд Ко., Інк. | Фармацевтична композиція антагоніста рецептора тахікініну у формі наночастинок |
WO2003053220A2 (en) | 2001-12-17 | 2003-07-03 | Corixa Corporation | Compositions and methods for the therapy and diagnosis of inflammatory bowel disease |
IL162183A0 (en) * | 2001-12-21 | 2005-11-20 | Celator Technologies Inc | Polymer-lipid delivery vehicles and methods for the preparation thereof |
US20030129242A1 (en) * | 2002-01-04 | 2003-07-10 | Bosch H. William | Sterile filtered nanoparticulate formulations of budesonide and beclomethasone having tyloxapol as a surface stabilizer |
AU2003210517A1 (en) * | 2002-02-04 | 2003-09-02 | Elan Pharma International, Ltd. | Drug nanoparticles with lysozyme surface stabiliser |
US20040101566A1 (en) * | 2002-02-04 | 2004-05-27 | Elan Pharma International Limited | Novel benzoyl peroxide compositions |
US20030164219A1 (en) * | 2002-02-20 | 2003-09-04 | Joerg Brahm | Headliner/duct assembly and welding process therefor |
WO2003075952A1 (en) * | 2002-03-05 | 2003-09-18 | Board Of Regents, The University Of Texas System | Methods of enhancing immune induction involving mda-7 |
AU2003222027A1 (en) * | 2002-03-20 | 2003-10-08 | Elan Pharma International Limited | Fast dissolving dosage forms having reduced friability |
US20080220075A1 (en) * | 2002-03-20 | 2008-09-11 | Elan Pharma International Ltd. | Nanoparticulate compositions of angiogenesis inhibitors |
EP1490030B2 (en) * | 2002-03-20 | 2010-07-14 | Elan Pharma International Limited | Nanoparticulate compositions of angiogenesis inhibitors |
EP1800666A1 (en) * | 2002-03-20 | 2007-06-27 | Elan Pharma International Limited | Nanoparticulate compositions of angiogenesis inhibitors |
US20040076586A1 (en) * | 2002-03-28 | 2004-04-22 | Reinhard Koening | Compositions and methods for delivering pharmaceutically active agents using nanoparticulates |
WO2003087763A2 (en) | 2002-04-03 | 2003-10-23 | Celltech R & D, Inc. | Association of polymorphisms in the sost gene region with bone mineral density |
US7332469B2 (en) | 2002-04-05 | 2008-02-19 | Board Of Regents The University Of Texas System | Intrapleural single-chain urokinase alone or complexed to its soluble receptor protects against pleural adhesions |
ES2380318T3 (es) | 2002-04-12 | 2012-05-10 | Alkermes Pharma Ireland Limited | Formulaciones nanoparticulares de megestrol |
US9101540B2 (en) * | 2002-04-12 | 2015-08-11 | Alkermes Pharma Ireland Limited | Nanoparticulate megestrol formulations |
US20100226989A1 (en) * | 2002-04-12 | 2010-09-09 | Elan Pharma International, Limited | Nanoparticulate megestrol formulations |
US20040105889A1 (en) * | 2002-12-03 | 2004-06-03 | Elan Pharma International Limited | Low viscosity liquid dosage forms |
US7101576B2 (en) * | 2002-04-12 | 2006-09-05 | Elan Pharma International Limited | Nanoparticulate megestrol formulations |
EP1503737B1 (en) * | 2002-05-06 | 2009-01-07 | Elan Pharma International Limited | Nanoparticulate nystatin formulations |
DE60328486D1 (de) * | 2002-05-24 | 2009-09-03 | Angiotech Int Ag | Zusammensetzungen und verfahren zur beschichtung medizinischer implantate |
US8313760B2 (en) * | 2002-05-24 | 2012-11-20 | Angiotech International Ag | Compositions and methods for coating medical implants |
US20070264348A1 (en) * | 2002-05-24 | 2007-11-15 | Elan Pharma International, Ltd. | Nanoparticulate fibrate formulations |
KR100530369B1 (ko) * | 2002-05-27 | 2005-11-22 | 이영환 | 항암물질에 나노입자를 결합시킨 주사 제형의 약물 시스템 |
WO2003103632A1 (en) * | 2002-06-10 | 2003-12-18 | Elan Pharma International, Ltd. | Nanoparticulate polycosanol formulations and novel polycosanol combinations |
EP1531799A1 (en) * | 2002-06-10 | 2005-05-25 | Elan Pharma International Limited | Nanoparticulate formulations comprising hmg coa reductase inhibitor derivatives ("statins"), novel combinations thereof as well as manufacturing of these pharmaceutical compositions |
US20040001889A1 (en) | 2002-06-25 | 2004-01-01 | Guohua Chen | Short duration depot formulations |
JP4776229B2 (ja) * | 2002-07-16 | 2011-09-21 | エラン ファーマ インターナショナル,リミティド | 安定なナノ粒子活性物質の液体投与組成物 |
CA2818693C (en) | 2002-08-12 | 2016-05-17 | Jennerex, Inc. | Methods and compositions concerning poxviruses and cancer |
RU2005103625A (ru) | 2002-08-12 | 2005-08-20 | Пфайзер Продактс Инк. (Us) | Фармацевтические композиции полуупорядоченных лекарств и полимеров |
DK1553927T3 (da) * | 2002-09-11 | 2011-01-31 | Elan Pharma Int Ltd | Gel-stabiliserede, nanopartikulære aktivstof-sammensætninger |
CA2500908A1 (en) * | 2002-10-04 | 2004-04-22 | Elan Pharma International Limited | Gamma irradiation of solid nanoparticulate active agents |
US6966990B2 (en) | 2002-10-11 | 2005-11-22 | Ferro Corporation | Composite particles and method for preparing |
GB0304367D0 (en) * | 2003-02-26 | 2003-04-02 | Pharma Mar Sau | Methods for treating psoriasis |
ES2365012T3 (es) * | 2002-11-12 | 2011-09-20 | Elan Pharma International Limited | Formas farmacéuticas sólidas de desintegración rápida que no son friables y que comprenden pululano. |
EP1935407A1 (en) * | 2002-12-03 | 2008-06-25 | Elan Pharma International Limited | Low viscosity liquid dosage forms |
SI1585548T1 (sl) | 2002-12-09 | 2018-11-30 | Abraxis Bioscience, Llc | Sestave in metode odmerjanja farmakoloških sredstev |
EP2218448B1 (en) * | 2002-12-13 | 2015-09-23 | Durect Corporation | Oral drug delivery system comprising high viscosity liquid carrier materials |
WO2004058216A2 (en) * | 2002-12-17 | 2004-07-15 | Elan Pharma International Ltd. | Milling microgram quantities of nanoparticulate candidate compounds |
ES2639812T3 (es) | 2003-01-06 | 2017-10-30 | Corixa Corporation | Ciertos compuestos de fosfato de aminoalquil glucosaminida y sus usos |
US7960522B2 (en) | 2003-01-06 | 2011-06-14 | Corixa Corporation | Certain aminoalkyl glucosaminide phosphate compounds and their use |
JP4469846B2 (ja) * | 2003-01-31 | 2010-06-02 | エラン ファーマ インターナショナル,リミティド | ナノ粒子状トピラメート製剤 |
US20040208833A1 (en) * | 2003-02-04 | 2004-10-21 | Elan Pharma International Ltd. | Novel fluticasone formulations |
US6931888B2 (en) * | 2003-02-07 | 2005-08-23 | Ferro Corporation | Lyophilization method and apparatus for producing particles |
US7083748B2 (en) * | 2003-02-07 | 2006-08-01 | Ferro Corporation | Method and apparatus for continuous particle production using supercritical fluid |
US8512727B2 (en) | 2003-03-03 | 2013-08-20 | Alkermes Pharma Ireland Limited | Nanoparticulate meloxicam formulations |
KR20060002793A (ko) * | 2003-03-03 | 2006-01-09 | 더 보드 오브 리전츠, 더 유니버시티 오브 텍사스 시스템 | Mda-7을 포함하는 방법 및 조성물 |
US20100297252A1 (en) | 2003-03-03 | 2010-11-25 | Elan Pharma International Ltd. | Nanoparticulate meloxicam formulations |
US7459442B2 (en) * | 2003-03-07 | 2008-12-02 | Schering Corporation | Substituted azetidinone compounds, processes for preparing the same, formulations and uses thereof |
MXPA05009501A (es) * | 2003-03-07 | 2005-10-18 | Schering Corp | Compuestos de azetidinona sustituidos, formulaciones y usos de los mismos para el tratamiento de hipercolesterolemia. |
US7235543B2 (en) * | 2003-03-07 | 2007-06-26 | Schering Corporation | Substituted azetidinone compounds, processes for preparing the same, formulations and uses thereof |
CN102697737B (zh) * | 2003-04-03 | 2014-03-19 | 杰西.L.-S.奥 | 负载肿瘤靶向药物的颗粒 |
US20060008531A1 (en) * | 2003-05-08 | 2006-01-12 | Ferro Corporation | Method for producing solid-lipid composite drug particles |
DE10323597A1 (de) * | 2003-05-19 | 2004-12-09 | Aesculap Ag & Co. Kg | Medizintechnisches Produkt, Verfahren zu seiner Herstellung und Verwendung |
BRPI0410646A (pt) * | 2003-05-20 | 2006-07-04 | Ranbaxy Lab Ltd | composições farmacêuticas de acitretina e processo para sua preparação |
EP1626742A1 (en) * | 2003-05-22 | 2006-02-22 | Elan Pharma International Limited | Sterilization of dispersions of nanoparticulate active agents with gamma radiation |
JP4688802B2 (ja) | 2003-06-16 | 2011-05-25 | セルテック アール アンド ディー, インコーポレイテッド | 骨の鉱化作用を増大させるためのスクレロスチンに特異的な抗体および方法 |
US20050106310A1 (en) * | 2003-07-02 | 2005-05-19 | Green John H. | Designed particle agglomeration |
ES2559828T3 (es) | 2003-07-16 | 2016-02-16 | Protiva Biotherapeutics Inc. | ARN de interferencia encapsulado en lípidos |
ATE415946T1 (de) * | 2003-08-08 | 2008-12-15 | Elan Pharma Int Ltd | Neue metaxalon-zusammensetzungen |
US7419996B2 (en) * | 2003-08-13 | 2008-09-02 | The University Of Houston | Parenteral and oral formulations of benzimidazoles |
GB0327723D0 (en) * | 2003-09-15 | 2003-12-31 | Vectura Ltd | Pharmaceutical compositions |
AU2004285468B2 (en) | 2003-10-22 | 2011-02-24 | Fred Hutchinson Cancer Research Center | Methods, compositions and devices for inducing stasis in cells, tissues, organs, and organisms |
ES2366646T3 (es) * | 2003-11-05 | 2011-10-24 | Elan Pharma International Limited | Composiciones en forma de nanopartículas que tienen un péptido como estabilizante superficial. |
AU2004293463A1 (en) * | 2003-11-20 | 2005-06-09 | Angiotech International Ag | Implantable sensors and implantable pumps and anti-scarring agents |
WO2005051511A1 (ja) * | 2003-11-28 | 2005-06-09 | Mitsubishi Chemical Corporation | 有機化合物微粒子の製造方法 |
CA2548220A1 (en) * | 2003-12-01 | 2005-09-09 | Introgen Therapeutics, Inc. | Use of mda-7 to inhibit infection by pathogenic organisms |
US20070281041A1 (en) * | 2004-03-02 | 2007-12-06 | Introgen Therapeutics, Inc. | Compositions and Methods Involving MDA-7 for the Treatment of Cancer |
WO2005095950A1 (en) * | 2004-03-30 | 2005-10-13 | Pfizer Products Inc. | Method and device for evaluation of pharmaceutical compositions |
US20050220866A1 (en) * | 2004-04-02 | 2005-10-06 | Dr. Reddy's Laboratories Limited | Novel capsule formulations of etoposide for oral use |
AU2005285513B2 (en) | 2004-05-25 | 2011-02-24 | Oregon Health And Science University | SIV and HIV vaccination using RhCMV- and HCMV-based vaccine vectors |
US7871632B2 (en) * | 2004-07-12 | 2011-01-18 | Adventrx Pharmaceuticals, Inc. | Compositions for delivering highly water soluble drugs |
KR20070043894A (ko) * | 2004-08-19 | 2007-04-25 | 알자 코포레이션 | 제어 방출형 나노입자 활성제 제제 제형 및 방법 |
EP1797934A4 (en) * | 2004-09-07 | 2009-09-02 | Mitsubishi Chem Corp | METHOD FOR MANUFACTURING FINULY PARTICULATE SUBSTANCE AND FINALLY PARTICULATE SUBSTANCE |
EP1809329B1 (en) * | 2004-09-17 | 2011-12-21 | Durect Corporation | Sustained local anesthetic composition containing saib |
WO2006036278A2 (en) | 2004-09-18 | 2006-04-06 | University Of Maryland, Baltimore | THERAPEUTIC AGENTS TARGETING THE NCCa-ATP CHANNEL AND METHODS OF USE THEREOF |
AU2005287090A1 (en) | 2004-09-18 | 2006-03-30 | Department Of Veterans Affairs | Therapeutic agents targeting the NCca-ATP channel and methods of use thereof |
JP5324098B2 (ja) * | 2004-11-16 | 2013-10-23 | アルケルメス ファーマ アイルランド リミテッド | 注射可能なナノ粒子のオランザピン製剤 |
US20090155331A1 (en) * | 2005-11-16 | 2009-06-18 | Elan Pharma International Limited | Injectable nanoparticulate olanzapine formulations |
UA89513C2 (uk) * | 2004-12-03 | 2010-02-10 | Элан Фарма Интернешнл Лтд. | Стабільна композиція з наночастинок ралоксифену гідрохлориду |
MX2007007342A (es) * | 2004-12-15 | 2007-12-11 | Elan Pharma Int Ltd | Formulaciones de tacrolimus nanoparticuladas. |
WO2006069098A1 (en) * | 2004-12-22 | 2006-06-29 | Elan Pharma International Ltd. | Nanoparticulate bicalutamide formulations |
MX2007008212A (es) * | 2005-01-06 | 2007-08-16 | Elan Pharma Int Ltd | Formulaciones de candesartan en nanoparticulas. |
CA2597329C (en) * | 2005-02-08 | 2016-10-11 | Board Of Regents, The University Of Texas System | Compositions and methods involving mda-7 for the treatment of cancer |
EP1853234A2 (en) * | 2005-02-15 | 2007-11-14 | Elan Pharma International Limited | Aerosol and injectable formulations of nanoparticulate benzodiazepine |
PL1853250T3 (pl) | 2005-02-18 | 2012-03-30 | Abraxis Bioscience Llc | Kombinacje i sposoby podawania środków terapeutycznych oraz terapia skojarzona |
US8735394B2 (en) | 2005-02-18 | 2014-05-27 | Abraxis Bioscience, Llc | Combinations and modes of administration of therapeutic agents and combination therapy |
CA2598441A1 (en) * | 2005-02-24 | 2006-08-31 | Elan Pharma International Limited | Nanoparticulate formulations of docetaxel and analogues thereof |
AU2005100176A4 (en) * | 2005-03-01 | 2005-04-07 | Gym Tv Pty Ltd | Garbage bin clip |
WO2006096462A1 (en) * | 2005-03-03 | 2006-09-14 | Elan Pharma International Limited | Nanoparticulate compositions of heterocyclic amide derivatives |
WO2006099121A2 (en) * | 2005-03-10 | 2006-09-21 | Elan Pharma International Limited | Formulations of a nanoparticulate finasteride, dutasteride and tamsulosin hydrochloride, and mixtures thereof |
BRPI0606283A2 (pt) * | 2005-03-16 | 2009-06-09 | Elan Pharma Int Ltd | formulações de antagonista de receptor de leucotrieno/corticosteróide em nanopartìcula |
CN101198316A (zh) * | 2005-03-17 | 2008-06-11 | 伊兰制药国际有限公司 | 纳米微粒双膦酸盐组合物 |
WO2006101972A2 (en) * | 2005-03-17 | 2006-09-28 | Elan Pharma International Limited | Injectable compositions of nanoparticulate immunosuppressive compounds |
MX2007011772A (es) * | 2005-03-23 | 2007-12-05 | Elan Pharma Int Ltd | Formulaciones de antihistaminico y corticosteroide de materia en nanoparticulas. |
EP2392347A3 (en) | 2005-03-31 | 2012-01-18 | GlaxoSmithKline Biologicals S.A. | Vaccines against chlamydial infection |
JP2008535921A (ja) * | 2005-04-12 | 2008-09-04 | エラン・ファルマ・インターナショナル・リミテッド | シクロスポリンを含むナノ粒子および放出調節された組成物 |
US20060246141A1 (en) * | 2005-04-12 | 2006-11-02 | Elan Pharma International, Limited | Nanoparticulate lipase inhibitor formulations |
BRPI0607537A2 (pt) * | 2005-04-12 | 2009-09-15 | Elan Pharma Int Ltd | formulações de derivado de quinazolina nanoparticulado |
ITMI20050739A1 (it) * | 2005-04-22 | 2006-10-23 | Effebi Spa | Piastrina di connsessione valvola-attuatore |
JP5749881B2 (ja) | 2005-04-22 | 2015-07-15 | ユニヴェルシテ デ ジュネーブ | ポリラクチド組成物およびその使用 |
KR101352806B1 (ko) | 2005-04-29 | 2014-02-17 | 인펙셔스 디지즈 리서치 인스티튜트 (아이디알아이) | 결핵균 감염을 예방 또는 치료하기 위한 신규한 방법 |
US7592429B2 (en) | 2005-05-03 | 2009-09-22 | Ucb Sa | Sclerostin-binding antibody |
US8003108B2 (en) | 2005-05-03 | 2011-08-23 | Amgen Inc. | Sclerostin epitopes |
WO2006132752A1 (en) * | 2005-05-10 | 2006-12-14 | Elan Pharma International Limited | Nanoparticulate and controlled release compositions comprising vitamin k2 |
JP2008540550A (ja) * | 2005-05-10 | 2008-11-20 | エラン・ファルマ・インターナショナル・リミテッド | ビタミンk2を含むナノ粒子および制御放出組成物 |
US20100028439A1 (en) * | 2005-05-23 | 2010-02-04 | Elan Pharma International Limited | Nanoparticulate stabilized anti-hypertensive compositions |
AU2006309295B2 (en) * | 2005-06-03 | 2012-04-26 | Elan Pharma International Limited | Nanoparticulate acetaminophen formulations |
CA2610448A1 (en) * | 2005-06-03 | 2006-12-14 | Elan Pharma International, Limited | Nanoparticulate imatinib mesylate formulations |
WO2006133045A1 (en) * | 2005-06-03 | 2006-12-14 | Elan Pharma International, Limited | Nanoparticulate benidipine compositions |
WO2008073068A1 (en) | 2005-06-08 | 2008-06-19 | Elan Pharma International Limited | Nanoparticulate and controlled release compositions comprising cefditoren |
EP1898882B1 (en) * | 2005-06-09 | 2009-10-28 | Elan Pharma International Limited | Nanoparticulate ebastine formulations |
AU2006259606A1 (en) * | 2005-06-13 | 2006-12-28 | Elan Pharma International, Limited | Nanoparticulate clopidogrel and aspirin combination formulations |
US20060280787A1 (en) * | 2005-06-14 | 2006-12-14 | Baxter International Inc. | Pharmaceutical formulation of the tubulin inhibitor indibulin for oral administration with improved pharmacokinetic properties, and process for the manufacture thereof |
MX2007015183A (es) * | 2005-06-14 | 2008-02-19 | Baxter Int | Formulaciones farmaceuticas para minimizar las interacciones farmaco-farmaco. |
US20100221327A1 (en) * | 2005-06-15 | 2010-09-02 | Elan Pharma International Limited | Nanoparticulate azelnidipine formulations |
CA2613466A1 (en) * | 2005-06-22 | 2007-01-04 | Elan Pharma International, Limited | Nanoparticulate megestrol formulations |
US20070015719A1 (en) * | 2005-07-07 | 2007-01-18 | Elan Pharma International Limited | Nanoparticulate clarithromycin formulations |
US20070027105A1 (en) | 2005-07-26 | 2007-02-01 | Alza Corporation | Peroxide removal from drug delivery vehicle |
WO2007016597A2 (en) * | 2005-07-29 | 2007-02-08 | The Regents Of The University Of California | Targeting tnf-alpha converting enzyme (tace)-dependent growth factor shedding in cancer therapy |
GB0516549D0 (en) * | 2005-08-12 | 2005-09-21 | Sulaiman Brian | Milling system |
US8980246B2 (en) | 2005-09-07 | 2015-03-17 | Sillajen Biotherapeutics, Inc. | Oncolytic vaccinia virus cancer therapy |
WO2007030668A2 (en) * | 2005-09-07 | 2007-03-15 | Jennerex Biotherapeutics Ulc | Systemic treatment of metastatic and/or systemically-disseminated cancers using gm-csf-expressing poxviruses |
JP2009507925A (ja) * | 2005-09-13 | 2009-02-26 | エラン ファーマ インターナショナル リミテッド | ナノ粒子タダラフィル製剤 |
US20070148100A1 (en) * | 2005-09-15 | 2007-06-28 | Elan Pharma International, Limited | Nanoparticulate aripiprazole formulations |
WO2007041079A2 (en) * | 2005-09-30 | 2007-04-12 | Alza Corporation | Banded controlled release nanoparticle active agent formulation dosage forms and methods |
KR20080080119A (ko) * | 2005-11-15 | 2008-09-02 | 백스터 인터내셔널 인코포레이티드 | 리폭시게나제 억제제의 조성물 |
CN101360422B (zh) | 2005-11-23 | 2013-10-23 | 得克萨斯大学体系董事会 | 致癌Ras特异性细胞毒化合物及其使用方法 |
ES2812250T3 (es) * | 2005-11-28 | 2021-03-16 | Marinus Pharmaceuticals Inc | Formulaciones de ganaxolona y procedimientos para la preparación y uso de las mismas |
US20090062341A1 (en) | 2005-11-28 | 2009-03-05 | Dalton James T | Nuclear receptor binding agents |
WO2007120368A2 (en) | 2006-01-09 | 2007-10-25 | The Regents Of The University Of California | Immunostimulatory combinations for vaccine adjuvants |
WO2007092944A2 (en) * | 2006-02-08 | 2007-08-16 | Introgen Therapeutics, Inc. | Compositions and methods involving gene therapy and proteasome modulation |
US8367112B2 (en) * | 2006-02-28 | 2013-02-05 | Alkermes Pharma Ireland Limited | Nanoparticulate carverdilol formulations |
US20080166411A1 (en) * | 2006-04-10 | 2008-07-10 | Pfizer Inc | Injectable Depot Formulations And Methods For Providing Sustained Release Of Poorly Soluble Drugs Comprising Nanoparticles |
WO2007123468A1 (en) * | 2006-04-24 | 2007-11-01 | Bruce Medical Ab | Polymer-based anti-cancer agents |
JP4204634B2 (ja) * | 2006-05-15 | 2009-01-07 | 株式会社荏原製作所 | 難水溶性医薬 |
NZ573555A (en) * | 2006-05-30 | 2012-09-28 | Elan Pharma Int Ltd | Nanoparticulate posaconazole formulations |
JP2009543797A (ja) * | 2006-07-10 | 2009-12-10 | エラン ファーマ インターナショナル,リミティド | ナノ粒子ソラフェニブ製剤 |
CL2007002567A1 (es) | 2006-09-08 | 2008-02-01 | Amgen Inc | Proteinas aisladas de enlace a activina a humana. |
US8652782B2 (en) | 2006-09-12 | 2014-02-18 | Longhorn Vaccines & Diagnostics, Llc | Compositions and methods for detecting, identifying and quantitating mycobacterial-specific nucleic acids |
US9481912B2 (en) | 2006-09-12 | 2016-11-01 | Longhorn Vaccines And Diagnostics, Llc | Compositions and methods for detecting and identifying nucleic acid sequences in biological samples |
US8097419B2 (en) | 2006-09-12 | 2012-01-17 | Longhorn Vaccines & Diagnostics Llc | Compositions and method for rapid, real-time detection of influenza A virus (H1N1) swine 2009 |
US8080645B2 (en) * | 2007-10-01 | 2011-12-20 | Longhorn Vaccines & Diagnostics Llc | Biological specimen collection/transport compositions and methods |
US8481023B2 (en) | 2006-09-15 | 2013-07-09 | Ottawa Hospital Research Institute | Oncolytic rhabdovirus |
CA2663962A1 (en) | 2006-09-19 | 2008-03-27 | Asuragen, Inc. | Mir-15, mir-26, mir-31,mir-145, mir-147, mir-188, mir-215, mir-216, mir-331, mmu-mir-292-3p regulated genes and pathways as targets for therapeutic intervention |
MX2009003092A (es) * | 2006-09-22 | 2009-05-08 | Labopharm Inc | Composiciones y metodos para suministro de farmaco dirigido a ph. |
US8466154B2 (en) | 2006-10-27 | 2013-06-18 | The Board Of Regents Of The University Of Texas System | Methods and compositions related to wrapping of dehydrons |
US8337883B2 (en) | 2006-11-03 | 2012-12-25 | Durect Corporation | Transdermal delivery systems |
EP2097450A2 (en) * | 2006-11-10 | 2009-09-09 | Amgen Inc. | Antibody-based diagnostics and therapeutics |
WO2008133722A2 (en) * | 2006-11-10 | 2008-11-06 | Ucb Pharma S.A. | Anti human sclerostin antibodies |
EP2567975A3 (en) | 2006-11-21 | 2013-07-03 | The Regents of The University of California | Modulation of RHAMM (CD168) for selective adipose tissue development |
BRPI0717721A2 (pt) | 2006-11-28 | 2013-10-29 | Marinus Pharmaceuticals | "partículas complexadas de drogas, composição farmacêutica, uso de uma composição farmacêutica, partículas complexadas de droga estabilizadas no tamanho, método para a preparação de partículas estabilizadas da droga, composição farmacêutica sólida, comprimido oral ingerível e composição líquida em nanopartículas estabilizadas no tamanho" |
WO2008065502A1 (en) * | 2006-11-29 | 2008-06-05 | Pfizer Products Inc. | Pharmaceutical compositions based on a) nanoparticles comprising enteric polymers and b) casein |
PE20081506A1 (es) | 2006-12-12 | 2008-12-09 | Infinity Discovery Inc | Formulaciones de ansamicina |
WO2008080047A2 (en) * | 2006-12-23 | 2008-07-03 | Baxter International Inc. | Magnetic separation of fine particles from compositions |
US9511075B2 (en) | 2007-01-12 | 2016-12-06 | The University Of Maryland, Baltimore | Targeting NCCA-ATP channel for organ protection following ischemic episode |
AU2008214095B2 (en) | 2007-02-02 | 2014-07-10 | Baylor College Of Medicine | Compositions and methods for the treatment of metabolic disorders |
WO2008098160A1 (en) | 2007-02-09 | 2008-08-14 | University Of Maryland, Baltimore | Antagonists of a non-selective cation channel in neural cells |
KR20080084528A (ko) | 2007-03-15 | 2008-09-19 | 제네렉스 바이오테라퓨틱스 인크. | 종양살상형 백시니아 바이러스 암 치료 |
MX351247B (es) * | 2007-04-04 | 2017-10-05 | Infectious Disease Res Institute Star | Composiciones inmunogenicas que comprenden polipeptidos de mycobacterium tuberculosis y fusiones de los mismos. |
US9725485B2 (en) | 2012-05-15 | 2017-08-08 | University Of Florida Research Foundation, Inc. | AAV vectors with high transduction efficiency and uses thereof for gene therapy |
EP2191001B1 (en) | 2007-04-09 | 2016-06-08 | University of Florida Research Foundation, Inc. | Raav vector compositions having tyrosine-modified capsid proteins and methods for use |
WO2008125940A2 (en) * | 2007-04-17 | 2008-10-23 | Pfizer Products Inc. | Nanoparticles comprising non-crystalline drug |
US20100080852A1 (en) * | 2007-05-03 | 2010-04-01 | Ronald Arthur Beyerinck | Phamaceutical composition comprising nanoparticles and casein |
WO2008135855A2 (en) * | 2007-05-03 | 2008-11-13 | Pfizer Products Inc. | Nanoparticles comprising a cholesteryl ester transfer protein inhibitor and a nonionizable polymer |
US8309129B2 (en) * | 2007-05-03 | 2012-11-13 | Bend Research, Inc. | Nanoparticles comprising a drug, ethylcellulose, and a bile salt |
CA2686756A1 (en) * | 2007-05-11 | 2008-11-20 | F. Hoffmann-La Roche Ag | Pharmaceutical compositions for poorly soluble drugs |
US20080293814A1 (en) * | 2007-05-22 | 2008-11-27 | Deepak Tiwari | Concentrate esmolol |
US8722736B2 (en) * | 2007-05-22 | 2014-05-13 | Baxter International Inc. | Multi-dose concentrate esmolol with benzyl alcohol |
US8426467B2 (en) * | 2007-05-22 | 2013-04-23 | Baxter International Inc. | Colored esmolol concentrate |
WO2008149230A2 (en) | 2007-06-04 | 2008-12-11 | Pfizer Products Inc. | Nanoparticles comprising drug, a non-ionizable cellulosic polymer and tocopheryl polyethylene glycol succinate |
ES2465216T3 (es) | 2007-06-04 | 2014-06-05 | Ben Gurion University Of The Negev Research And Development Authority | Compuestos de triarilo y composiciones que comprenden los mismos |
US8974827B2 (en) * | 2007-06-04 | 2015-03-10 | Bend Research, Inc. | Nanoparticles comprising a non-ionizable cellulosic polymer and an amphiphilic non-ionizable block copolymer |
CA2691199C (en) | 2007-06-22 | 2017-09-12 | Marc J. Simard | Inhibitors of ncca-atp channels for therapy |
EP2178518A2 (en) * | 2007-07-13 | 2010-04-28 | Bend Research, Inc | Nanoparticles comprising ionizable, poorly water soluble cellulosic polymers |
US9683256B2 (en) | 2007-10-01 | 2017-06-20 | Longhorn Vaccines And Diagnostics, Llc | Biological specimen collection and transport system |
US11041215B2 (en) | 2007-08-24 | 2021-06-22 | Longhorn Vaccines And Diagnostics, Llc | PCR ready compositions and methods for detecting and identifying nucleic acid sequences |
US10004799B2 (en) | 2007-08-27 | 2018-06-26 | Longhorn Vaccines And Diagnostics, Llc | Composite antigenic sequences and vaccines |
EP2185196B1 (en) | 2007-08-27 | 2014-06-11 | Longhorn Vaccines & Diagnostics, LLC | Immunogenic compositions and methods |
US20090130210A1 (en) * | 2007-09-11 | 2009-05-21 | Raheja Praveen | Pharmaceutical compositions of sirolimus |
CL2008002775A1 (es) * | 2007-09-17 | 2008-11-07 | Amgen Inc | Uso de un agente de unión a esclerostina para inhibir la resorción ósea. |
EP3020832A1 (en) | 2007-10-01 | 2016-05-18 | Longhorn Vaccines and Diagnostics, LLC | Biological specimen collection and transport system and methods of use |
US11041216B2 (en) | 2007-10-01 | 2021-06-22 | Longhorn Vaccines And Diagnostics, Llc | Compositions and methods for detecting and quantifying nucleic acid sequences in blood samples |
JP2011506319A (ja) | 2007-12-06 | 2011-03-03 | デュレクト コーポレーション | 疼痛、関節炎症状、または慢性疾患に伴う炎症の治療に有用な方法 |
WO2009073215A1 (en) * | 2007-12-06 | 2009-06-11 | Bend Research, Inc. | Pharmaceutical compositions comprising nanoparticles and a resuspending material |
US9233078B2 (en) * | 2007-12-06 | 2016-01-12 | Bend Research, Inc. | Nanoparticles comprising a non-ionizable polymer and an Amine-functionalized methacrylate copolymer |
US20090238867A1 (en) * | 2007-12-13 | 2009-09-24 | Scott Jenkins | Nanoparticulate Anidulafungin Compositions and Methods for Making the Same |
WO2009079471A1 (en) | 2007-12-14 | 2009-06-25 | Amgen Inc. | Method for treating bone fracture with anti-sclerostin antibodies |
ES2509490T3 (es) * | 2007-12-24 | 2014-10-17 | Sun Pharma Advanced Research Company Limited | Nanodispersión |
US8865223B2 (en) * | 2008-02-11 | 2014-10-21 | Technion Research And Development Foundation Ltd. | Beta-casein assemblies for mucosal delivery of therapeutic bioactive agents |
US8865222B2 (en) * | 2008-02-11 | 2014-10-21 | Technion Research And Development Foundation Ltd. | Beta-casein assemblies for enrichment of food and beverages and methods of preparation thereof |
EP2252269A1 (en) * | 2008-02-11 | 2010-11-24 | Technion Research and Development Foundation, Ltd. | Casein particles encapsulating therapeutically active agents and uses thereof |
US8871276B2 (en) | 2008-02-11 | 2014-10-28 | Technion Research And Development Foundation Ltd. | Beta-casein assemblies for mucosal delivery of therapeutic bioactive agents |
WO2009117401A2 (en) * | 2008-03-21 | 2009-09-24 | Elan Pharama International Limited | Compositions for site-specific delivery of imatinib and methods of use |
US8258111B2 (en) | 2008-05-08 | 2012-09-04 | The Johns Hopkins University | Compositions and methods related to miRNA modulation of neovascularization or angiogenesis |
US20090311335A1 (en) * | 2008-06-12 | 2009-12-17 | Scott Jenkins | Combination of a triptan and an nsaid |
EP2309991B1 (en) * | 2008-06-16 | 2019-03-06 | Pfizer Inc | Therapeutic polymeric nanoparticles comprising vinca alkaloids and methods of making and using same |
CN106434576A (zh) | 2008-06-26 | 2017-02-22 | Atyr 医药公司 | 包含具有非常规生物活性的甘氨酰‑tRNA合成酶的组合物和方法 |
WO2010009075A1 (en) * | 2008-07-14 | 2010-01-21 | The University Of North Carolina At Chapel Hill | Methods and compositions comprising crystalline nanoparticles of hydrophobic compounds |
WO2010013224A2 (en) * | 2008-07-31 | 2010-02-04 | Santosh Kumar Kar | Curcumin nanoparticles and methods of producing the same |
CZ2008523A3 (cs) * | 2008-08-29 | 2009-10-14 | Fyzikální ústav AV CR, v.v.i. | Zpusob prípravy hybridních nanocástic z aglomerátu nanocástic komplexních vícesložkových oxidu kovu |
EP2719380A3 (en) | 2008-09-16 | 2014-07-30 | University of Maryland, Baltimore | SUR1 inhibitors for therapy |
US20100099775A1 (en) * | 2008-10-17 | 2010-04-22 | Alpharx Inc. | Method for ameliorating of post-anesthetic recovery |
US20100260844A1 (en) | 2008-11-03 | 2010-10-14 | Scicinski Jan J | Oral pharmaceutical dosage forms |
US8765817B1 (en) | 2008-12-03 | 2014-07-01 | Arrowhead Center, Inc. | Selective inhibitors of EG5 motors and methods of use |
US8349899B1 (en) | 2008-12-03 | 2013-01-08 | Arrowhead Center, Inc. | Selective inhibitors of EG5 motors and methods of use |
JP5739816B2 (ja) | 2008-12-19 | 2015-06-24 | バクスター・インターナショナル・インコーポレイテッドBaxter International Incorp0Rated | Tfpiインヒビターおよび使用法 |
DK3045043T3 (da) | 2009-02-26 | 2020-08-03 | Relmada Therapeutics Inc | Orale farmaceutiske sammensætninger af 3-hydroxy-n-methylmorphinan med forlænget frigivelse og fremgangsmåde til anvendelse |
US20120004185A1 (en) | 2009-02-27 | 2012-01-05 | Atyr Pharma, Inc. | Polypeptide structural motifs associated with cell signaling activity |
CN102428175A (zh) | 2009-03-16 | 2012-04-25 | 盘古生物制药有限公司 | 包含具有非经典生物活性的组氨酰-tRNA合成酶剪接变异体的组合物及方法 |
CA2757289A1 (en) | 2009-03-31 | 2010-10-21 | Atyr Pharma, Inc. | Compositions and methods comprising aspartyl-trna synthetases having non-canonical biological activities |
EP2421559B1 (en) | 2009-04-24 | 2016-07-20 | Vanderbilt University | Anti-tgf-beta induction of bone growth |
WO2010135714A2 (en) | 2009-05-22 | 2010-11-25 | The Methodist Hospital Research Institute | Methods for modulating adipocyte expression using microrna compositions |
FR2945950A1 (fr) | 2009-05-27 | 2010-12-03 | Elan Pharma Int Ltd | Compositions de nanoparticules anticancereuses et procedes pour les preparer |
WO2010138539A2 (en) | 2009-05-27 | 2010-12-02 | Elan Pharma International Ltd. | Reduction of flake-like aggregation in nanoparticulate active agent compositions |
WO2010138263A2 (en) | 2009-05-28 | 2010-12-02 | University Of Massachusetts | Novel aav 's and uses thereof |
EP2442805A4 (en) | 2009-06-19 | 2012-11-21 | Sun Pharma Advanced Res Co Ltd | NANODISPERSION OF A MEDICINE AND METHOD FOR PREPARING THE SAME |
EP2451496B1 (en) | 2009-07-10 | 2015-07-22 | Boston Scientific Scimed, Inc. | Use of nanocrystals for a drug delivery balloon |
WO2011008737A2 (en) | 2009-07-13 | 2011-01-20 | The University Of North Carolina At Chapel Hill | Engineered aerosol particles, and associated methods |
EP3100610A1 (en) | 2009-07-24 | 2016-12-07 | Baylor College Of Medicine | Methods of modulation of branched chain acids and uses thereof |
HUE038708T2 (hu) | 2009-09-14 | 2018-11-28 | Sillajen Biotherapeutics Inc | Onkolitikus vaccinia vírus kombinációs rákterápia |
MX365946B (es) | 2009-12-10 | 2019-06-19 | Turnstone Lp | Rabdovirus oncolitico. |
US20110150885A1 (en) | 2009-12-11 | 2011-06-23 | Atyr Pharma, Inc. | Aminoacyl trna synthetases for modulating hematopoiesis |
EP2509625B1 (en) | 2009-12-11 | 2015-01-28 | Atyr Pharma, Inc. | Histidyl trna synthetases for reducing inflammation |
MX2012007055A (es) | 2009-12-18 | 2012-10-15 | Amgen Inc | Agentes epitopes de enlace wise. |
KR20120129927A (ko) | 2010-01-27 | 2012-11-28 | 글락소 그룹 리미티드 | 변형된 투베르쿨로시스 항원 |
TWI438009B (zh) * | 2010-02-19 | 2014-05-21 | Teikoku Pharma Usa Inc | 紫杉烷前-乳劑調配物及其製造與使用之方法 |
KR101948463B1 (ko) | 2010-03-19 | 2019-02-14 | 박스알타 인코퍼레이티드 | Tfpi 저해제 및 사용 방법 |
SG10201502759TA (en) | 2010-04-23 | 2015-06-29 | Univ Florida | Raav-guanylate cyclase compositions and methods for treating leber's congenital amaurosis-1 (lca1) |
WO2011133901A2 (en) | 2010-04-23 | 2011-10-27 | University Of Massachusetts | Aav-based treatment of cholesterol-related disorders |
CA2833908C (en) | 2010-04-23 | 2021-02-09 | University Of Massachusetts | Cns targeting aav vectors and methods of use thereof |
AU2011248625B2 (en) | 2010-04-26 | 2017-01-05 | Pangu Biopharma Limited | Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of cysteinyl-tRNA synthetase |
EP2563381B1 (en) | 2010-04-27 | 2017-08-09 | aTyr Pharma, Inc. | Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of isoleucyl trna synthetases |
CN103097524B (zh) | 2010-04-28 | 2016-08-03 | Atyr医药公司 | 与丙氨酰-tRNA合成酶的蛋白片段相关的治疗、诊断和抗体组合物的创新发现 |
CN103118693B (zh) | 2010-04-29 | 2017-05-03 | Atyr 医药公司 | 与缬氨酰‑tRNA合成酶的蛋白片段相关的治疗、诊断和抗体组合物的创新发现 |
AU2011248490B2 (en) | 2010-04-29 | 2016-11-10 | Pangu Biopharma Limited | Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of Asparaginyl tRNA synthetases |
CN102970990A (zh) | 2010-05-03 | 2013-03-13 | 帝国制药美国公司 | 非水性紫杉烷前-乳剂制剂以及制备和使用该制剂的方法 |
WO2011140132A2 (en) | 2010-05-03 | 2011-11-10 | Atyr Pharma, Inc. | Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of phenylalanyl-alpha-trna synthetases |
CN103096925A (zh) | 2010-05-03 | 2013-05-08 | Atyr医药公司 | 与精氨酰-tRNA合成酶的蛋白片段相关的治疗、诊断和抗体组合物的创新发现 |
ES2668207T3 (es) | 2010-05-03 | 2018-05-17 | Atyr Pharma, Inc. | Descubrimiento innovador de composiciones terapéuticas, de diagnóstico y de anticuerpos relacionadas con fragmentos de proteínas de metionil-ARNt sintetasas |
US9062302B2 (en) | 2010-05-04 | 2015-06-23 | Atyr Pharma, Inc. | Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of p38 multi-tRNA synthetase complex |
SG185465A1 (en) | 2010-05-14 | 2012-12-28 | Amgen Inc | High concentration antibody formulations |
CN103200953B (zh) | 2010-05-14 | 2017-02-15 | Atyr 医药公司 | 与苯丙氨酰‑β‑tRNA合成酶的蛋白片段相关的治疗、诊断和抗体组合物的创新发现 |
CN103096914B (zh) | 2010-05-17 | 2015-08-12 | Atyr医药公司 | 与亮氨酰-tRNA合成酶的蛋白片段相关的治疗、诊断和抗体组合物的创新发现 |
AU2011258106B2 (en) | 2010-05-27 | 2017-02-23 | Pangu Biopharma Limited | Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of glutaminyl-tRNA synthetases |
EP2575857B1 (en) | 2010-06-01 | 2018-01-24 | aTyr Pharma, Inc. | Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of lysyl-trna synthetases |
WO2012021247A2 (en) | 2010-07-12 | 2012-02-16 | Atyr Pharma, Inc. | Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of glycyl-trna synthetases |
US10865445B2 (en) | 2010-08-18 | 2020-12-15 | Fred Hutchinson Cancer Research Center | Methods for alleviating facioscapulohumeral dystrophy (FSHD) by N siRNA molecule inhibiting the expression of DUX4-FL |
WO2012027611A2 (en) | 2010-08-25 | 2012-03-01 | Atyr Pharma, Inc. | INNOVATIVE DISCOVERY OF THERAPEUTIC, DIAGNOSTIC, AND ANTIBODY COMPOSITIONS RELATED TO PROTEIN FRAGMENTS OF TYROSYL-tRNA SYNTHETASES |
US20130345079A1 (en) | 2010-10-27 | 2013-12-26 | Infectious Disease Research Institute | Mycobacterium tuberculosis antigens and combinations thereof having high seroreactivity |
EA201390676A1 (ru) | 2010-11-08 | 2013-11-29 | Инфекшес Дизиз Рисерч Инститьют | Вакцины, содержащие полипептиды неспецифической нуклеозидгидролазы и стерол 24-c-метилтрансферазы (smt), для лечения и диагностики лейшманиоза |
BR112013017096A2 (pt) | 2011-01-04 | 2020-09-01 | Jennerex Inc. | composição e métodos de indução de resposta citotóxica dependente de complemento mediado por anticorpo específico de tumor em animal tendo tumor, de geração de anticorpos in vivo, de inibição do crescimento ou morte de célula de câncer, para tratar indivíduo com câncer, para adaptar de terapia de câncer para indivíduo com câncer e para identificar antígeno específico de tumor |
WO2012097093A2 (en) | 2011-01-11 | 2012-07-19 | Fate Therapeutics, Inc. | Novel wnt compositions and therapeutic uses of such compositions |
WO2012103328A1 (en) | 2011-01-26 | 2012-08-02 | The Methodist Hospital Research Institute | Labeled, non- peptidic multivalent integrin alpha -v - beta - 3 antagonists, compositions containing them and their use |
MY165507A (en) | 2011-02-03 | 2018-03-28 | Mirna Therapeutics Inc | Synthetic mimics of mir-34 |
CN103459598B (zh) | 2011-02-03 | 2016-08-10 | 米尔纳医疗股份有限公司 | Mir-124的合成模拟物 |
WO2012110469A1 (en) | 2011-02-17 | 2012-08-23 | F. Hoffmann-La Roche Ag | A process for controlled crystallization of an active pharmaceutical ingredient from supercooled liquid state by hot melt extrusion |
EA201391248A1 (ru) | 2011-03-01 | 2014-05-30 | Эмджен Инк. | Биспецифические связывающие агенты |
EA029956B1 (ru) | 2011-03-25 | 2018-06-29 | Эмджен Инк. | Кристаллы антител против склеростина и составы на их основе |
LT3404041T (lt) | 2011-04-19 | 2020-08-25 | Amgen Inc. | Osteoporozės gydymo būdas |
EP2710037B1 (en) | 2011-05-19 | 2019-07-31 | The Regents of The University of Michigan | Integrin alpha-2 binding agents and use thereof to inhibit cancer cell proliferation |
WO2012170384A1 (en) | 2011-06-06 | 2012-12-13 | Chevron Phillips Chemical Company Lp | Use of metallocene compounds for cancer treatment |
US9364532B2 (en) | 2011-06-08 | 2016-06-14 | Children's Hospital Of Eastern Ontario Research Institute Inc. | Compositions and methods for glioblastoma treatment |
ES2710452T3 (es) | 2011-06-10 | 2019-04-25 | Bluebird Bio Inc | Vectores de terapia génica para la adrenoleucodistrofia y la adrenomieloneuropatía |
US20150030586A1 (en) | 2011-06-21 | 2015-01-29 | Sarah Ellen Warren | Compositions and methods for the therapy and diagnosis of cancer |
PL2734634T3 (pl) | 2011-07-22 | 2020-03-31 | The University Of Chicago | Igf-1 do zastosowania do leczenia migreny |
ES2667554T3 (es) | 2011-08-04 | 2018-05-11 | Amgen Inc. | Método para el tratamiento de los defectos de espacio óseo |
US9655905B2 (en) | 2011-09-14 | 2017-05-23 | King Abdullah University Of Science And Technology | Treatment of sickle cell disease |
US9644005B2 (en) | 2011-09-21 | 2017-05-09 | King Abdullah University Of Science And Technology | Didemnin biosynthetic gene cluster in Tistrella mobilis |
AU2011377617B2 (en) | 2011-09-23 | 2018-03-08 | Bluebird Bio, Inc. | Improved gene therapy methods |
WO2013095736A2 (en) | 2011-09-27 | 2013-06-27 | The Methodist Hospital Research Institute | Gold-in-silicon nanoassembly for thermal therapy and methods of use |
ES2769270T3 (es) | 2011-09-30 | 2020-06-25 | Bluebird Bio Inc | Compuestos para transducción viral mejorada |
KR102110794B1 (ko) | 2011-10-31 | 2020-05-15 | 더 메서디스트 하스피틀 리서치 인스티튜트 | 인간의 신경교종을 치료하기 위한 모노아마이드 옥시다아제(Monoamide oxidase,MAO) 타겟팅/시커(seeker) 부분(moiety)을 포함하는 조성물 |
US10208086B2 (en) | 2011-11-11 | 2019-02-19 | Fred Hutchinson Cancer Research Center | Cyclin A1-targeted T-cell immunotherapy for cancer |
JP2015501802A (ja) | 2011-11-17 | 2015-01-19 | ザ リージェンツ オブ ザ ユニバーシティ オブ コロラド,ア ボディー コーポレイトTHE REGENTS OF THE UNIVERSITY OF COLORADO,a body corporate | 眼への薬物送達を向上させるための方法および組成物、ならびに徐放性送達製剤 |
US20130177627A1 (en) * | 2011-11-18 | 2013-07-11 | Linda Einbond | Growth inhibitory effects of nanoparticles containing triterpene glycosides or triterpenes |
US9546367B2 (en) | 2011-12-07 | 2017-01-17 | Jenny Chee Ning Chang | siRNA compositions and methods for inhibiting gene expression in tumor initiating cells of breast cancer |
BR112014016108A2 (pt) | 2011-12-28 | 2018-09-11 | Amgen Inc | método de tratamento de perda óssea alvelar |
CN104203272A (zh) | 2012-01-26 | 2014-12-10 | 长角牛疫苗和诊断有限责任公司 | 复合抗原序列及疫苗 |
US20150024037A1 (en) | 2012-02-16 | 2015-01-22 | The University Of Toledo | Xenoantigen-Displaying Anti-Cancer Vaccines and Method of Making |
NZ629130A (en) | 2012-03-21 | 2016-10-28 | Baxalta Inc | Tfpi inhibitors and methods of use |
US20140128431A1 (en) | 2012-04-03 | 2014-05-08 | Hoffmann-Laroche Inc. | Pharmaceutical composition with improved bioavailability, safety and tolerability |
AR092821A1 (es) | 2012-04-20 | 2015-05-06 | Sucampo Ag | Conjugado de derivado de acido graso-polimero |
EP2852380A4 (en) | 2012-05-23 | 2016-01-20 | Univ Ohio State | LIPID-COATED ALBUMIN NANOPARTICLE COMPOSITIONS AND METHOD FOR THE PREPARATION AND METHOD OF USE THEREOF |
EP3626267A1 (en) | 2012-07-05 | 2020-03-25 | UCB Pharma, S.A. | Treatment for bone diseases |
WO2014039189A1 (en) | 2012-08-01 | 2014-03-13 | Mcnally Elizabeth | Mitigating tissue damage and fibrosis via latent transforming growth factor beta binding protein (ltbp4) |
BR112015002483A2 (pt) | 2012-08-03 | 2017-11-07 | Infectious Disease Res Inst | composições e métodos para o tratamento de uma infecção ativa por mycobacterium tuberculosis |
JO3685B1 (ar) | 2012-10-01 | 2020-08-27 | Teikoku Pharma Usa Inc | صيغ التشتيت الجسيمي للتاكسين غير المائي وطرق استخدامها |
UY35148A (es) | 2012-11-21 | 2014-05-30 | Amgen Inc | Immunoglobulinas heterodiméricas |
CN104936589A (zh) | 2013-01-22 | 2015-09-23 | 霍夫曼-拉罗奇有限公司 | 具有改善的生物利用度的药物组合物 |
SG11201505960VA (en) | 2013-02-01 | 2015-08-28 | Santa Maria Biotherapeutics Inc | Administration of an anti-activin-a compound to a subject |
RU2684211C2 (ru) | 2013-02-21 | 2019-04-04 | Тёрнстоун Лимитед Партнершип | Композиция вакцины |
US10208012B2 (en) | 2013-03-13 | 2019-02-19 | Board Of Regents, The University Of Texas System | Compounds for treating inflammatory and hyperproliferative diseases |
US9572885B2 (en) | 2013-03-15 | 2017-02-21 | Durect Corporation | Compositions with a rheological modifier to reduce dissolution variability |
WO2014160987A2 (en) | 2013-03-28 | 2014-10-02 | Infectious Disease Research Institute | Vaccines comprising leishmania polypeptides for the treatment and diagnosis of leishmaniasis |
US9393202B2 (en) * | 2013-04-26 | 2016-07-19 | Chiesi Farmaceutici S.P.A | Particle size reduction of an antimuscarinic compound |
WO2014186746A1 (en) | 2013-05-16 | 2014-11-20 | University Of Florida Research Foundation, Inc. | HAIRPIN mRNA ELEMENTS AND METHODS FOR THE REGULATION OF PROTEIN TRANSLATION |
CR20160207A (es) | 2013-11-05 | 2016-08-10 | Ben Gurion Univ Of The Negev Res And Dev Authority | Compuestos para el tratamiento de la diabetes y las complicaciones que surgen de la misma enfermedad |
WO2015084625A1 (en) | 2013-12-02 | 2015-06-11 | Baylor College Of Medicine | Identification of a new polypeptide hormone for maintenance of optimal body weight and blood glucose |
CN110845615B (zh) | 2014-03-21 | 2023-10-20 | 艾伯维公司 | 抗-egfr抗体及抗体药物偶联物 |
KR20160143775A (ko) | 2014-04-08 | 2016-12-14 | 더 메서디스트 하스피틀 | iNOS-억제 조성물들 및 이들의 유방암 치료제로서의 용도 |
WO2015157500A1 (en) | 2014-04-09 | 2015-10-15 | Research Development Foundation | Class iia hdac inhibitors for the treatment of infection |
WO2015164786A1 (en) | 2014-04-25 | 2015-10-29 | University Of Massachusetts | Recombinant aav vectors useful for reducing immunity against transgene products |
MX2016016826A (es) | 2014-06-20 | 2017-08-28 | Aveo Pharmaceuticals Inc | Tratamiento de la enfermedad renal cronica y otra disfuncion renal utilizando un modulador gdf15. |
EP3157952B1 (en) | 2014-06-20 | 2021-12-22 | Aveo Pharmaceuticals, Inc. | Treatment of congestive heart failure and other cardiac dysfunction using a gdf15 modulator |
US10278986B2 (en) | 2014-08-14 | 2019-05-07 | The Regents Of The University Of Colorado, A Body Corporate | Antibody-siRNA conjugates and uses therefor |
JP2017532013A (ja) | 2014-09-01 | 2017-11-02 | アカデミア シニカAcademia Sinica | 寿命に関する動物モデル並びに寿命を延ばす及び腫瘍化を阻害する関連方法 |
EP3189143B1 (en) | 2014-09-04 | 2019-08-07 | Memorial Sloan-Kettering Cancer Center | Globin gene therapy for treating hemoglobinopathies |
HUE054670T2 (hu) | 2014-09-25 | 2021-09-28 | Aveo Pharmaceuticals Inc | Módszer cachexia visszafordítására és túlélés megnövelésére egy GDF15 modulátor és egy rákellenes szer adagolásával |
US10711270B2 (en) | 2014-10-03 | 2020-07-14 | University Of Massachusetts | High efficiency library-identified AAV vectors |
RU2738421C2 (ru) | 2014-10-21 | 2020-12-14 | Юниверсити Оф Массачусетс | Варианты рекомбинантных aav и их применения |
US10302644B2 (en) | 2014-11-04 | 2019-05-28 | Dana-Farber Cancer Institute, Inc. | Compositions and methods for treating multiple myeloma |
MA41142A (fr) | 2014-12-12 | 2017-10-17 | Amgen Inc | Anticorps anti-sclérostine et utilisation de ceux-ci pour traiter des affections osseuses en tant qu'élements du protocole de traitement |
CA2967468A1 (en) | 2014-12-16 | 2016-06-23 | Board Of Regents Of The University Of Nebraska | Gene therapy for juvenile batten disease |
US10166197B2 (en) | 2015-02-13 | 2019-01-01 | St. John's University | Sugar ester nanoparticle stabilizers |
MX2017011615A (es) | 2015-03-10 | 2018-04-11 | Univ Columbia | Construcciones de vectores virales adeno-asociados de glut1 recombinantes y métodos relacionados para restablecer la expresión de glut1. |
WO2016172026A1 (en) | 2015-04-20 | 2016-10-27 | The Board Of Regents Of The University Of Texas System | Clec11a is a bone growth agent |
EP3288957A4 (en) | 2015-05-01 | 2019-01-23 | Cocrystal Pharma, Inc. | NUCLEOSIDE ANALOGUE FOR THE TREATMENT OF VIRUSES OF THE FLAVIVIIDAE FAMILY AND CANCER |
EP3294448A4 (en) | 2015-05-14 | 2018-12-12 | Longhorn Vaccines and Diagnostics, LLC | Rapid methods for the extraction of nucleic acids from biological samples |
DK3302431T3 (da) * | 2015-06-04 | 2020-11-30 | Crititech Inc | Taxanpartikler og anvendelse deraf |
WO2016205615A1 (en) | 2015-06-17 | 2016-12-22 | The Johns Hopkins University | Tdp-43 in degenerative disease |
CA2998483C (en) | 2015-09-16 | 2022-09-06 | Dfb Soria, Llc | Delivery of drug nanoparticles and methods of use thereof |
EP3357396B1 (en) * | 2015-09-28 | 2019-11-06 | Sumitomo Osaka Cement Co., Ltd. | Method for manufacturing dishwasher/dryer |
WO2017066626A1 (en) | 2015-10-16 | 2017-04-20 | Marinus Pharmaceuticals, Inc. | Injectable neurosteroid formulations containing nanoparticles |
EP3364997B1 (en) | 2015-10-22 | 2024-01-17 | University of Massachusetts | Aspartoacylase gene therapy in the treatment of canavan disease |
KR20180104597A (ko) | 2015-11-07 | 2018-09-21 | 멀티비르 인코포레이티드 | 암 치료를 위한 종양 억제 유전자 요법 및 면역관문 봉쇄를 포함하는 조성물 |
KR20180136435A (ko) | 2016-01-27 | 2018-12-24 | 온코루스, 인크. | 종양 살상형 바이러스 벡터 및 그의 용도 |
US10695322B2 (en) | 2016-01-29 | 2020-06-30 | The Johns Hopkins University | Inhibitors of bacterial growth |
WO2017139643A1 (en) | 2016-02-12 | 2017-08-17 | University Of Massachusetts | Anti-angiogenic mirna therapeutics for inhibiting corneal neovascularization |
WO2017143112A2 (en) | 2016-02-17 | 2017-08-24 | The Johns Hopkins University | An oxazolidinone for treatment of infections with mycobacterium tuberculosis |
WO2017147215A1 (en) | 2016-02-22 | 2017-08-31 | The Methodist Hospital | Biomimetic proteolipid vesicle compositions and uses thereof |
WO2017147370A1 (en) | 2016-02-24 | 2017-08-31 | The Johns Hopkins University | Novel antiviral proteins and their uses in therapeutic methods |
AU2017225769B2 (en) | 2016-03-02 | 2023-01-05 | The Board Of Regents Of The University Of Texas System | Sting activating nanovaccine for immunotherapy |
HRP20211697T1 (hr) | 2016-03-03 | 2022-02-04 | University Of Massachusetts | Zatvorena linearna dupleks dnk za nevirusni prijenos gena |
WO2017155935A1 (en) | 2016-03-07 | 2017-09-14 | The Johns Hopkins University | Pharmaceutical agents targeting cancer stem cells |
GB201604124D0 (en) | 2016-03-10 | 2016-04-27 | Ucb Biopharma Sprl | Pharmaceutical formulation |
CN109790545A (zh) | 2016-03-10 | 2019-05-21 | 约翰·霍普金斯大学 | 产生不含聚集物的单体白喉毒素融合蛋白的方法和治疗用途 |
US11203626B2 (en) | 2016-03-10 | 2021-12-21 | The Johns Hopkins University | Methods of producing aggregate-free monomeric diphtheria toxin fusion proteins and therapeutic uses |
WO2017161155A1 (en) | 2016-03-17 | 2017-09-21 | The Johns Hopkins University | Methods for preventing or treating parkinson's disease by the farnesylation of paris |
EP3436609B1 (en) | 2016-03-30 | 2022-05-04 | The Johns Hopkins University | Olfr90 specificity and methods of detection |
CA3018989A1 (en) | 2016-04-04 | 2017-10-12 | Crititech, Inc. | Methods for solid tumor treatment |
US11016085B2 (en) | 2016-04-25 | 2021-05-25 | The Johns Hopkins University | ZNT8 assays for drug development and pharmaceutical compositions |
JP2019521095A (ja) | 2016-05-21 | 2019-07-25 | インフェクシャス ディズィーズ リサーチ インスティチュート | 二次性結核および非結核性マイコバクテリウム感染症を治療するための組成物および方法 |
TW202304996A (zh) | 2016-06-08 | 2023-02-01 | 美商艾伯維有限公司 | 抗-b7-h3抗體及抗體藥物結合物 |
BR112018075644A2 (pt) | 2016-06-08 | 2019-04-09 | Abbvie Inc. | anticorpos anti-cd98 e conjugados de anticorpo e fármaco |
US20200002421A1 (en) | 2016-06-08 | 2020-01-02 | Abbvie Inc. | Anti-b7-h3 antibodies and antibody drug conjugates |
MX2018015274A (es) | 2016-06-08 | 2019-10-07 | Abbvie Inc | Anticuerpos anti-cd98 y conjugados de anticuerpo y farmaco. |
EP3469000A1 (en) | 2016-06-08 | 2019-04-17 | AbbVie Inc. | Anti-b7-h3 antibodies and antibody drug conjugates |
MX2019000221A (es) | 2016-07-05 | 2020-02-07 | Univ Massachusetts | Suministro genetico de sfasl mediado por aav2 como una terapia neuro-protectora en el glaucoma. |
AU2017298385A1 (en) | 2016-07-19 | 2019-03-07 | University Of Pittsburgh - Of The Commonwealth System Of Higher Education | Oncolytic viruses targeting STAT3 |
CN109715151A (zh) | 2016-08-11 | 2019-05-03 | 奥维德医疗公司 | 用于治疗癫痫性紊乱的方法和组合物 |
US9963498B2 (en) | 2016-08-18 | 2018-05-08 | Wisconsin Alumni Research Foundation | Peptides that inhibit syndecan-1 activation of VLA-4 and IGF-1R |
US10391105B2 (en) | 2016-09-09 | 2019-08-27 | Marinus Pharmaceuticals Inc. | Methods of treating certain depressive disorders and delirium tremens |
MX2019003035A (es) | 2016-09-16 | 2019-09-13 | Infectious Disease Res Inst | Vacunas que comprenden polipeptidos de mycobacterium leprae para la prevencion, el tratamiento y el diagnostico de la lepra. |
US10457940B2 (en) | 2016-09-22 | 2019-10-29 | University Of Massachusetts | AAV treatment of Huntington's disease |
US11149275B2 (en) | 2016-10-10 | 2021-10-19 | The Johns Hopkins University | Device and method to treat esophageal disorders |
AU2017341849B2 (en) | 2016-10-13 | 2024-03-21 | University Of Massachusetts | AAV capsid designs |
CA3043160A1 (en) | 2016-11-08 | 2018-05-17 | University Of Miami | Anti-secretogranin iii (scg3) antibodies and uses thereof |
US20200009203A1 (en) | 2016-12-12 | 2020-01-09 | Multivir Inc. | Methods and compositions comprising viral gene therapy and an immune checkpoint inhibitor for treatment and prevention of cancer and infectious diseases |
US10434089B2 (en) | 2017-01-25 | 2019-10-08 | The Johns Hopkins University | Avibactam and carbapenems antibacterial agents |
DK4008344T3 (da) | 2017-01-27 | 2024-01-29 | Methodist Hospital | Kerne/skal struktur platform til immunterapi |
CA3053309A1 (en) | 2017-02-12 | 2018-08-16 | Ben-Gurion University Of The Negev Research And Development Authority | Telomerase activating compounds for use in fertility and related applications |
WO2018170196A1 (en) | 2017-03-15 | 2018-09-20 | Dfb Soria, Llc | Topical therapy for the treatment of skin malignancies using nanoparticles of taxanes |
AU2018261637A1 (en) | 2017-05-03 | 2019-12-12 | Biomarin Pharmaceutical Inc. | Improved lentiviruses for transduction of hematopoietic stem cells. |
US11680275B2 (en) | 2017-06-06 | 2023-06-20 | University Of Massachusetts | Self-regulating AAV vectors for safe expression of MeCP2 in rett syndrome |
JP2020523285A (ja) | 2017-06-09 | 2020-08-06 | クリチテック,インコーポレイテッド | 抗腫瘍粒子の嚢胞内注入による上皮嚢胞の治療 |
JP6840869B2 (ja) * | 2017-06-14 | 2021-03-10 | クリチテック,インコーポレイテッド | 肺障害の治療方法 |
US11892457B2 (en) | 2017-07-12 | 2024-02-06 | The Johns Hopkins University | Proteoliposome-based ZnT8 self-antigen for type 1 diabetes diagnosis |
AU2018306455A1 (en) | 2017-07-26 | 2020-02-27 | Virogin Biotech Canada Ltd | Oncolytic viral vectors and uses thereof |
WO2019028469A1 (en) | 2017-08-04 | 2019-02-07 | The Methodist Hospital | FUNCTIONALIZED POLYMER MITOCHONDRIAL COMPOSITIONS AND METHODS OF USE IN CELL TRANSPLANTATION AND FOR MODIFYING METABOLIC PHENOTYPE |
CN111315406A (zh) | 2017-09-08 | 2020-06-19 | 传染病研究所 | 包括皂苷的脂质体调配物及其使用方法 |
EP3691631A1 (en) | 2017-10-03 | 2020-08-12 | Crititech, Inc. | Local delivery of antineoplastic particles in combination with systemic delivery of immunotherapeutic agents for the treatment of cancer |
WO2019099613A1 (en) | 2017-11-16 | 2019-05-23 | University Of Maine System Board Of Trustees | Compositions and methods for modulating endothelial cell migration and angiogenesis |
EP3720509A4 (en) | 2017-12-06 | 2021-12-08 | Memorial Sloan-Kettering Cancer Center | GLOBING THERAPY FOR THE TREATMENT OF HEMOGLOBINOPATHIES |
WO2019134049A1 (en) | 2018-01-05 | 2019-07-11 | Bell John C | Modified vaccinia vectors |
US11497726B2 (en) | 2018-03-16 | 2022-11-15 | Dfb Soria, Ll. | Topical therapy for the treatment of cervical intraepithelial neoplasia (CIN) and cervical cancer using nanoparticles of taxanes |
KR20200135986A (ko) | 2018-03-19 | 2020-12-04 | 멀티비르 인코포레이티드 | 종양 억제인자 유전자 치료 및 cd122/cd132 작용제를 포함하는 암 치료를 위한 방법 및 조성물 |
CN112368051A (zh) | 2018-03-23 | 2021-02-12 | 马萨诸塞大学 | 用于治疗骨病的基因治疗剂 |
MX2020010092A (es) | 2018-03-30 | 2020-10-28 | Amgen Inc | Variantes de anticuerpo c-terminales. |
US11472848B2 (en) | 2018-04-27 | 2022-10-18 | University Of Massachusetts | AAV capsids identified by in vivo library selection |
SG11202009914SA (en) | 2018-05-08 | 2020-11-27 | Rutgers The State University Of New Jersey | Aav-compatible laminin-linker polymerization proteins |
KR102167755B1 (ko) | 2018-05-23 | 2020-10-19 | 주식회사 큐어바이오 | 단편화된 grs 폴리펩타이드, 이의 변이체 및 이들의 용도 |
MX2021003663A (es) | 2018-09-28 | 2021-05-28 | Harvard College | Reprogramacion celular para revertir el envejecimiento y promover la regeneracion de organos y tejidos. |
CA3113470A1 (en) | 2018-09-28 | 2020-04-02 | President And Fellows Of Harvard College | Mutant reverse tetracycline transactivators for expression of genes |
WO2020112967A1 (en) | 2018-11-29 | 2020-06-04 | University Of Massachusetts | Modulation of sptlc1 via recombinant adeno-associated vectors |
WO2020118142A1 (en) | 2018-12-07 | 2020-06-11 | Marinus Pharmaceuticals, Inc. | Ganaxolone for use in prophylaxis and treatment of pospartum depression |
WO2020114615A1 (en) | 2018-12-07 | 2020-06-11 | Baxalta GmbH | Bispecific antibodies binding factor ixa and factor x |
WO2020115283A1 (en) | 2018-12-07 | 2020-06-11 | Baxalta GmbH | Bispecific antibodies binding factor ixa and factor x |
AU2019406214A1 (en) | 2018-12-21 | 2021-08-05 | Northwestern University | Use of annexins in preventing and treating muscle membrane injury |
WO2020139977A1 (en) | 2018-12-26 | 2020-07-02 | Northwestern University | Use of glucocorticoid steroids in preventing and treating conditions of muscle wasting, aging and metabolic disorder |
US20220088221A1 (en) | 2019-01-12 | 2022-03-24 | The Methodist Hospital | Self-assembled peptide nanoparticle and use thereof |
WO2020163766A1 (en) | 2019-02-07 | 2020-08-13 | Baylor College Of Medicine | Periosteal skeletal stem cells in bone repair |
CA3131023A1 (en) | 2019-02-22 | 2020-08-27 | Michael R. Volkert | Oxr1 gene therapy |
US11717506B2 (en) | 2019-05-07 | 2023-08-08 | The Johns Hopkins University | Neuroprotective compounds for amyotrophic lateral sclerosis |
EP4009982A4 (en) | 2019-08-05 | 2023-08-09 | Marinus Pharmaceuticals, Inc. | GANAXOLONE FOR USE IN THE TREATMENT OF STATUS EPILEPTICUS |
CN114555814A (zh) | 2019-09-13 | 2022-05-27 | 罗特格斯新泽西州立大学 | Aav相容的层粘连蛋白-连接子聚合蛋白 |
CA3157063A1 (en) | 2019-10-10 | 2021-04-15 | Oncorus, Inc. | Dual viruses and dual oncolytic viruses and methods of treatment |
WO2021113644A1 (en) | 2019-12-05 | 2021-06-10 | Multivir Inc. | Combinations comprising a cd8+ t cell enhancer, an immune checkpoint inhibitor and radiotherapy for targeted and abscopal effects for the treatment of cancer |
AU2020395254A1 (en) | 2019-12-06 | 2022-06-02 | Marinus Pharmaceuticals, Inc. | Ganaxolone for use in treating tuberous sclerosis complex |
CN115666621A (zh) | 2020-01-13 | 2023-01-31 | 度勒科特公司 | 具有减少的杂质的持续释放药物递送系统及相关方法 |
KR20220144377A (ko) | 2020-01-30 | 2022-10-26 | 우모자 바이오파마 인코포레이티드 | 이중특이적 형질도입 촉진제 |
AU2021248577A1 (en) | 2020-03-31 | 2022-09-29 | Sichuan Univeristy | AAV capsids variants and uses thereof |
MX2023001586A (es) | 2020-08-07 | 2023-05-03 | Access To Advanced Health Inst | Saponinas purificadas y proceso cromatografico para purificacion de las mismas. |
KR20230117177A (ko) | 2020-12-03 | 2023-08-07 | 유니버시티 오브 매사추세츠 | 진행성 골화성 섬유이형성증을 위한 신규 유전자 치료제의개발 |
KR20220082558A (ko) | 2020-12-10 | 2022-06-17 | 재단법인 의약바이오컨버젼스연구단 | 면역 증진 활성이 있는 신규 crs 단편 펩타이드 및 이의 용도 |
AR124681A1 (es) | 2021-01-20 | 2023-04-26 | Abbvie Inc | Conjugados anticuerpo-fármaco anti-egfr |
JP2024505887A (ja) | 2021-01-27 | 2024-02-08 | ウモジャ バイオファーマ, インコーポレイテッド | 抗cd19キメラ抗原受容体を発現する細胞を生成するためのレンチウイルス |
WO2023092060A1 (en) | 2021-11-18 | 2023-05-25 | Cornell University | Microrna-dependent mrna switches for tissue-specific mrna-based therapies |
GB2614309A (en) | 2021-12-24 | 2023-07-05 | Stratosvir Ltd | Improved vaccinia virus vectors |
WO2023144393A1 (en) | 2022-01-28 | 2023-08-03 | Fundació Centre De Regulació Genòmica | Therapeutic cytokines and methods |
WO2023196851A1 (en) | 2022-04-06 | 2023-10-12 | President And Fellows Of Harvard College | Reversing aging of the central nervous system |
WO2023225569A1 (en) | 2022-05-17 | 2023-11-23 | Umoja Biopharma, Inc. | Manufacturing viral particles |
Family Cites Families (33)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US2671750A (en) * | 1950-09-19 | 1954-03-09 | Merck & Co Inc | Stable noncaking aqueous suspension of cortisone acetate and method of preparing the same |
JPS4932056B1 (ja) * | 1970-12-22 | 1974-08-27 | ||
US4107288A (en) * | 1974-09-18 | 1978-08-15 | Pharmaceutical Society Of Victoria | Injectable compositions, nanoparticles useful therein, and process of manufacturing same |
DK143689C (da) * | 1975-03-20 | 1982-03-15 | J Kreuter | Fremgangsmaade til fremstilling af en adsorberet vaccine |
DE3013839A1 (de) * | 1979-04-13 | 1980-10-30 | Freunt Ind Co Ltd | Verfahren zur herstellung einer aktivierten pharmazeutischen zusammensetzung |
FR2504408B1 (fr) * | 1981-04-24 | 1986-02-14 | Couvreur Patrick | Procede de preparation de particules submicroscopiques, particules ainsi obtenues et compositions pharmaceutiques les contenant |
SE8204244L (sv) * | 1982-07-09 | 1984-01-10 | Ulf Schroder | Kristalliserad kolhydratsmatris for biologiskt aktiva substanser |
CA1282405C (en) * | 1984-05-21 | 1991-04-02 | Michael R. Violante | Method for making uniformly sized particles from water-insoluble organic compounds |
US4826689A (en) * | 1984-05-21 | 1989-05-02 | University Of Rochester | Method for making uniformly sized particles from water-insoluble organic compounds |
CA1264566A (en) * | 1984-09-05 | 1990-01-23 | Tetsuji Iwasaki | Biocidal fine powder, its manufacturing method and a suspension for agricultural use containing the above powder |
GB8601100D0 (en) * | 1986-01-17 | 1986-02-19 | Cosmas Damian Ltd | Drug delivery system |
JPS62185013A (ja) * | 1986-02-08 | 1987-08-13 | Green Cross Corp:The | 易吸収性医薬組成物 |
JPS6479154A (en) * | 1986-09-29 | 1989-03-24 | Green Cross Corp | Benzoylurea compound |
EP0262560A3 (en) * | 1986-09-29 | 1989-07-05 | Ishihara Sangyo Kaisha, Ltd. | Benzoyl urea compound |
NL194638C (nl) * | 1986-12-19 | 2002-10-04 | Novartis Ag | Hydrosol die vaste deeltjes van een farmaceutisch actieve stof bevat en farmaceutisch preparaat dat deze hydrosol bevat. |
FR2608988B1 (fr) * | 1986-12-31 | 1991-01-11 | Centre Nat Rech Scient | Procede de preparation de systemes colloidaux dispersibles d'une substance, sous forme de nanoparticules |
FR2634397B2 (fr) * | 1986-12-31 | 1991-04-19 | Centre Nat Rech Scient | Procede de preparation de systemes colloidaux dispersibles d'une proteine sous forme de nanoparticules |
FR2608942B1 (fr) * | 1986-12-31 | 1991-01-11 | Centre Nat Rech Scient | Procede de preparation de systemes colloidaux dispersibles d'une substance, sous forme de nanocapsules |
IT1227626B (it) * | 1988-11-28 | 1991-04-23 | Vectorpharma Int | Farmaci supportati aventi velocita' di dissoluzione aumentata e procedimento per la loro preparazione |
JP2773895B2 (ja) * | 1989-04-25 | 1998-07-09 | 東京田辺製薬株式会社 | ダナゾール組成物 |
GB8914060D0 (en) * | 1989-06-19 | 1989-08-09 | Wellcome Found | Agents for potentiating the effects of antitumour agents and combating multiple drug resistance |
SE464743B (sv) * | 1989-06-21 | 1991-06-10 | Ytkemiska Inst | Foerfarande foer framstaellning av laekemedelspartiklar |
JP2642486B2 (ja) * | 1989-08-04 | 1997-08-20 | 田辺製薬株式会社 | 難溶性薬物の超微粒子化法 |
JP2687245B2 (ja) * | 1989-09-29 | 1997-12-08 | 富士写真フイルム株式会社 | 磁気記録媒体の製造方法 |
GB8923075D0 (en) * | 1989-10-13 | 1989-11-29 | Patterson Laurence H | Anti-cancer compounds |
DK546289D0 (da) * | 1989-11-02 | 1989-11-02 | Danochemo As | Carotenoidpulvere |
FR2660556B1 (fr) * | 1990-04-06 | 1994-09-16 | Rhone Poulenc Sante | Microspheres, leur procede de preparation et leur utilisation. |
US5091188A (en) * | 1990-04-26 | 1992-02-25 | Haynes Duncan H | Phospholipid-coated microcrystals: injectable formulations of water-insoluble drugs |
US5145684A (en) * | 1991-01-25 | 1992-09-08 | Sterling Drug Inc. | Surface modified drug nanoparticles |
AU642066B2 (en) * | 1991-01-25 | 1993-10-07 | Nanosystems L.L.C. | X-ray contrast compositions useful in medical imaging |
ATE150297T1 (de) * | 1992-06-10 | 1997-04-15 | Nanosystems Llc | Oberflaechenmodifizierte nsaid nanopartikeln |
US5298262A (en) * | 1992-12-04 | 1994-03-29 | Sterling Winthrop Inc. | Use of ionic cloud point modifiers to prevent particle aggregation during sterilization |
US5302401A (en) * | 1992-12-09 | 1994-04-12 | Sterling Winthrop Inc. | Method to reduce particle size growth during lyophilization |
-
1992
- 1992-07-01 US US07/908,125 patent/US5399363A/en not_active Expired - Lifetime
-
1993
- 1993-05-26 TW TW082104179A patent/TW281631B/zh active
- 1993-06-11 CA CA002098242A patent/CA2098242C/en not_active Expired - Lifetime
- 1993-06-18 UA UA93003037A patent/UA27746C2/uk unknown
- 1993-06-29 ES ES93201883T patent/ES2143488T3/es not_active Expired - Lifetime
- 1993-06-29 AU AU41560/93A patent/AU675432B2/en not_active Ceased
- 1993-06-29 AT AT93201883T patent/ATE190835T1/de not_active IP Right Cessation
- 1993-06-29 MY MYPI93001273A patent/MY109946A/en unknown
- 1993-06-29 EP EP93201883A patent/EP0577215B1/en not_active Expired - Lifetime
- 1993-06-29 DK DK93201883T patent/DK0577215T3/da active
- 1993-06-29 JP JP5158808A patent/JPH07165562A/ja active Pending
- 1993-06-29 SG SG1996005605A patent/SG55089A1/en unknown
- 1993-06-29 DE DE69328136T patent/DE69328136T2/de not_active Expired - Lifetime
- 1993-06-30 CZ CZ931316A patent/CZ131693A3/cs unknown
- 1993-06-30 SK SK681-93A patent/SK281608B6/sk unknown
- 1993-06-30 RU RU93046256/14A patent/RU2130781C1/ru not_active IP Right Cessation
- 1993-06-30 IL IL106198A patent/IL106198A0/xx not_active IP Right Cessation
- 1993-06-30 MX MX9303950A patent/MX9303950A/es unknown
- 1993-07-01 NZ NZ248042A patent/NZ248042A/en unknown
- 1993-07-01 NO NO932403A patent/NO308193B1/no unknown
- 1993-07-01 CN CN93108050A patent/CN1063630C/zh not_active Expired - Fee Related
- 1993-07-01 HU HU9301917A patent/HUT64832A/hu unknown
- 1993-07-01 FI FI933040A patent/FI933040A/fi unknown
- 1993-07-01 KR KR1019930012267A patent/KR940001881A/ko active Search and Examination
-
1994
- 1994-12-28 US US08/365,267 patent/US5494683A/en not_active Expired - Lifetime
-
2008
- 2008-05-27 JP JP2008138475A patent/JP4709873B2/ja not_active Expired - Lifetime
-
2010
- 2010-08-24 JP JP2010186927A patent/JP2010265324A/ja active Pending
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP4709873B2 (ja) | ナノ粒子組成物 | |
Jacob et al. | Emerging role of nanosuspensions in drug delivery systems | |
RU2186562C2 (ru) | Композиции, представляющие собой микрочастицы веществ, нерастворимых в воде, и способ их изготовления | |
Möschwitzer | Drug nanocrystals in the commercial pharmaceutical development process | |
KR100200061B1 (ko) | 표면이 변형된 미립자 형태의 약제 | |
Niwa et al. | Design of self-dispersible dry nanosuspension through wet milling and spray freeze-drying for poorly water-soluble drugs | |
US5571536A (en) | Formulations of compounds as nanoparticulate dispersions in digestible oils or fatty acids | |
EP0644755B1 (en) | Surface modified nsaid nanoparticles | |
JPH06227967A (ja) | ナノ粒子を含む組成物及びその製造方法 | |
JP2010047579A (ja) | セルロース系表面安定剤を用いたヒト免疫不全ウイルス(hiv)プロテアーゼ阻害剤のナノ結晶製剤及びそのような製剤の製造方法 | |
JPH06227968A (ja) | ナノ粒子を含む組成物及びその製造方法 | |
JPH06211646A (ja) | ナノ粒子を含む組成物及びその製造方法 | |
JP2020531424A (ja) | メロキシカムを含有する注射用医薬組成物、およびその製造方法 | |
US7666307B2 (en) | Particle size reduction of bioactive compounds | |
EP0808154B1 (en) | Formulations of compounds as nanoparticulate dispersions in digestible oils or fatty acids | |
Taheri | Formulation, optimization and characterization of gemfibrozil nanocrystals prepared by wet milling technique | |
Barman et al. | Improving flow property of nifedipine loaded solid-lipid nanoparticles by means of silica for oral solid dosage form | |
Sheng et al. | Continuous and scalable process for the production of hollow crystals of a poorly water-soluble active pharmaceutical ingredient for dissolution enhancement and inhaled delivery | |
SK76595A3 (en) | Antacid composition and method of production | |
Patel | Formulation and Evaluation of Benidipine Nano-suspension by Precipitation Method using Central Composite Design | |
Kumar B et al. | In-vitro–In-vivo Characterization of Glimepiride Lipid Nanoparticulates Prepared by Combined Approach of Precipitation and Complexation | |
AU743917B2 (en) | Compositions comprising microparticles of water-insoluble substances |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
RD02 | Notification of acceptance of power of attorney |
Free format text: JAPANESE INTERMEDIATE CODE: A7422 Effective date: 20090626 |
|
RD04 | Notification of resignation of power of attorney |
Free format text: JAPANESE INTERMEDIATE CODE: A7424 Effective date: 20090626 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20090902 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20091126 |
|
A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20091201 |
|
A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20100426 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20101008 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20110318 |
|
EXPY | Cancellation because of completion of term |